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CHAPTER 1
General Introduction

Invasive streptococcal pathogens are a global health concern. Streptococcal pathogens
continue to pose significant challenges for the treatment and prevention of invasive disease worldwide
(96, 218, 228, 258). The emergence of antibiotic resistance among streptococcal isolates adds to the
relevance of this problem (151, 252). Those at highest risk for invasive streptococcal disease include
young children, the elderly and the immunocompromised (228). The major human streptococcal
pathogens associated with severe morbidity and mortality include Streptococcus pyogenes,
Streptococcus agalactiae, and Streptococcus pneumoniae. These species are often asymptomatically
carried on the nasal, oral or vaginal mucosal surfaces, and can easily be transmitted to others. For
example, vaginal colonization of S. agalactiae is a precondition for in utero transmission to newborns
(49).
Infections of S. pyogenes (group A streptococcus, GAS) can manifest as acute symptoms
including pharyngitis, cellulitis and pyoderma to more invasive diseases such as necrotizing fasciitis,
sepsis, pneumonia and streptococcal toxic shock syndrome (188).

Additionally non-suppurative

sequelae such as acute rheumatic fever and glomerulonephritis can complicate recovery efforts even
after the infection has been resolved (69). The recent resurgence of invasive GAS infections has
impacted many populations of the world (50), and placed huge economic burdens in both developing
and developed counties, with cost estimates up to $500 million per year in the United States alone
(227).
Streptococcus agalactiae (group B streptococcus, GBS) is a significant cause of morbidity and
mortality in both newborns, the elderly and immunocompromised (25, 293). Neonatal GBS disease
can manifest as either early onset with symptoms including respiratory failure and pneumonia
progressing into bacteremia and septic shock, or late onset which is characterized as a bloodstream
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infection with high risk of meningitis (207). While advancements in diagnosis and prophylactic
treatment have reduced early-onset neonatal mortality (78), the persistence of S. agalactiae-related still
births, prematurity and late-onset disease remains a significant problem (107, 255). Additionally, an
increased incidence of skin infections, pneumonia and bacteremia among the elderly and
immunocompromised (83, 97), along with an emerging resistance to penicillin, clindamycin and
erythromycin among individual isolates is cause for concern (123, 150, 263).
Streptococcus pneumoniae is a major cause of otitis media in children, as well as invasive
diseases including pneumonia with bacteremia and/or empyema, and meningitis in newborns and the
elderly.

The World Health Organization estimates that 1 million children die of invasive

pneumococcal disease every year, mostly in developing countries (309). Moreover, pneumococcal
infections are the leading cause of death from a vaccine-preventable illness in children < 5 years of age
(52). As with the other streptococcal pathogens, a huge economic burden is associated with S.
pneumoniae infection despite current vaccination efforts (280). A licensed 23-valent pneumococcal
polysaccharide vaccine has been in use since the late 1970s for the prevention of adult pneumococcal
bacteremia (59); however, the burden of adult nonbacteremic pneumococcal pneumonia remains a
significant challenge.
Because the adult polysaccharide vaccine is not effective in children < 3 years of age, conjugate
vaccines were developed for use in newborn vaccinations. The first licensed multi-valent
pneumococcal vaccine for newborns (PCV7) was composed of polysaccharides from 7 different S.
pneumoniae serotypes conjugated to the diphtheria toxoid. PCV7 vaccination programs were initially
extremely successful with not only significant reductions in invasive pneumococcal disease, but also a
decreased frequency of antimicrobial resistant pneumococci (133). The selective pressure imparted by
PCV7 vaccination resulted in the emergence of new clinically relevant serotypes including the severe
multi-drug resistant serotype 19A (70, 128), such that by 2010 the Centers for Disease Control and
Prevention reported that 63% of invasive pneumococcal disease in children < 5 years of age was due to
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non-PCV7 protected serotypes (53).

The vaccine was recently reformulated and licensed for

protection against 13 clinically relevant serotypes (1, 3, 4, 6A/B/C, 7F, 9V, 14, 18C, 19A/F and 23F)
(1-2); however, there are 96 documented pneumococcal serotypes with varying capsular
polysaccharide structures categorized into 46 different serogroups based on immunological crossreactivity (118, 261). Thus the possibility for new and emerging variants still exists.
Although there are no licensed vaccines for either S. agalactiae or S. pyogenes, significant
developmental efforts have been undertaken. Five GBS serotypes (Ia, Ib, II, III, V) account for 96% of
neonatal cases and 88% of invasive GBS disease in adults (229, 315). Vaccines for all the 5 major
capsular polysaccharide serotypes conjugated to tetanus toxoid have been constructed and show
enhanced immunogenicity in early clinical trials (11-15, 220); however, the emergence of new
serotypes is also a concern as observed with S. pneumoniae. Additional surface molecules such as the
Sip protein and immunogenic proteins from the GBS pilus are being investigated for their effectiveness
as alternative vaccine targets to the capsular polysaccharide (38, 137, 193).
The lack of a clear strategy for primary protection against S. pyogenes infection strengthens the
need for an effective GAS vaccine (270).

The most advanced vaccine in development is both

multivalent and type specific, made of short tandem peptides from the N-terminal region of the major
surface M-protein (130). The S. pyogenes M protein has long been investigated for GAS vaccine
design; however, early observations related to the cross-reactivity of protective antibodies with human
tissues such as heart (72) brain (40), kidney or joint cartilage (10) led to initial concerns about
vaccination safety, though many of these concerns have been addressed in current formulations.
Additional pitfalls of this current vaccine relate to the high antigentic variability of the M protein (99,
138).

Epidemiological studies of endemic populations with high GAS disease prevalence show

extensive variability in M serotypes (146, 239). One study in particular identified 31 different GAS M
serotypes within a small Australian Aboriginal community over a 2 year period, with up to 11 different
serotypes occurring at any given time (27).

Such variability could hinder the vaccine efficacy,
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especially in countries with high endemic GAS disease (270).

Other vaccines currently in

development target the conserved C-repeat region of the M protein (35-36, 238), the conserved GAS
carbohydrate (129), C5a peptidase (136), streptococcal fibronectin-binding protein 1 (Sfb1) (292) and
streptolysin S (73), though most are far from clinical trials.
As outlined above, invasive streptococcal pathogens present a significant public health concern.
Problems with treatment and prevention of invasive human streptococcal pathogens emphasize the
importance of understanding both mechanisms of streptococcal pathogenesis and surface adaptations
for the design of efficient vaccines and treatment options. The use of model streptococcal pathogens
such as Streptococcus iniae to address these issues may prove invaluable for the identification of novel
vaccine targets and development of effective therapeutics. The use of S. iniae to investigate the
challenges that exist for infection control of streptococcal pathogens is discussed in greater detail in the
following sections.
Streptococcus iniae is an invasive systemic pathogen and model pathogen. Streptococcus
iniae is a -hemolytic, Lancefield serogroup negative, Gram positive streptococci originally isolated
from the subcutaneous abscess of an Amazon freshwater dolphin (Inia geoffrensis) suffering from
acute “golf ball disease” (231-232). Aquatic species infected with S. iniae typically suffer from severe
skin lesions, septicemia and meningoencephalitis (9). Disease epidemics are often associated with
seasonal increases in water temperature or poor water quality (22, 39, 144). Streptococcocis of fish
was not widely observed prior to the 1970s (247); however, the increased use of aquaculture for
maintaining fish populations has resulted in the pandemic spread of S. iniae, with documented
outbreaks affecting approximately 30 different aquatic species and losses totaling $100 million
annually (4).
The enormity of loss associated with S. iniae outbreaks prompted the development of a
formalin-killed vaccine (90), and its successful implementation in large farming operations provided
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significant relief for trout fisheries within Israel (22). This success was short-lived when within 2
years the emergence of an unprotected strain with altered serotype specificity resulted in massive
outbreaks in previously vaccinated fish populations (7, 19, 165). Reformulation of the vaccine was
again followed by the emergence of a new variant that produced copious amounts of extracellular
polysaccharides (EPS) (94). The new EPS producing strains were hyperinflammatory and displayed
an increase in disease severity and mortality (93). Thus development of a reliable vaccine for S. iniae
has been challenging and will require a better understanding of streptococcal surface variability (4).
The emergence of unprotected strains of S. iniae following large scale vaccination equates to the
problems observed with human vaccination against S. pneumoniae (128). Testing the efficacy of novel
streptococcal vaccine targets using S. iniae could be an efficient way to determine their long term
effectiveness in large populations under strong selective pressure, minimizing the emergence of
unprotected variant strains. Such targets could then be further validated for their effectiveness against
human streptococcal pathogens. Novel targets for S. iniae vaccine development that are currently
being investigated include a putative iron binding protein Sip11 (58), hydrophobic membrane protein
MtsB (320) and a DNA based vaccine expressing a secretory antigen Sia10 under the control of a
cytomegalovirus immediate-early promoter (278).
The specific identification of S. iniae among fish populations for epidemiologic monitoring has
been difficult due to its similarity to several other streptococcal species including Streptococcus
parauberis and Streptococcus difficilis. Thus even PCR based diagnosis toward various targets
including the 16S rRNA gene, chaperonin HSP60 or the 16S-23S rRNA intergenic region has been
problematic (26, 109, 319). A breakthrough occurred when a S. iniae gene encoding a lactate oxidase
(lctO) was identified, and found to be limited to a few streptococcal species such as S. equi and S.
pyogenes (108). Novel primer sets were designed (LOX1/LOX2) which allowed for the specific
identification of S. iniae through PCR amplification of lctO (194), providing a tool for determining the
presence of S. inaie in large aquiculture systems. During random screening of a fish farm in Northern
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Australia, a novel lctO variant was identified that produced a larger, more efficient version of the
enzyme, which may provide a competitive advantage against other S. iniae strains (212). Examples
such as this highlight the selective pressures placed on emerging pathogenic strains in aquaculture, and
underscore the importance of developing efficient identification and control strategies.
Documented cases of zoonitic S. iniae infection began in the mid 1990s when in the span of a
year 4 patients developed bacteremic cellulitis from injuries obtained while handling fresh fish (304).
Since then sporadic cases have been documented worldwide, all occurring after injury from infected
fish (95, 171, 277, 305). Human clinical isolates of S. iniae show increased virulence in animal
infection models compared to commensal fish strains (101). Furthermore, recent human isolates
display enhanced survival and replication over earlier isolates when cultured in whole blood (95).
Nonetheless, S. inaie is not considered an emerging pathogen of human concern (95, 260).
S. iniae has been used as a model pathogen for the study of systemic streptococcal infection in
several native hosts including hybrid striped bass (42, 44), rainbow trout (18, 41, 88), barramundi (8),
tilapia (88, 320) and zebrafish (202-203, 214). Numerous virulence factors have been described that
severely influence the morbidity and mortality caused by this pathogen. Many of these factors are also
critical for virulence of human streptococcal pathogens as well, providing relevance for the use of S.
iniae as a model pathogen for the study of invasive streptococcal infection.
In concordance with many invasive pathogens, the majority of virulence factors described for
S. iniae protect against opsonophagocytic killing by neutrophils (81, 110, 196, 306). S. iniae contains
a homolog of the major streptococcal M protein, which can bind fibrinogen as well as the FC region of
immunoglobulin to inhibit opsonization (8, 18). S. iniae also produces a C5a peptidase to hydrolyze
the neutrophil chemoattractant complement factor C5a (180); however, unlike the S. pyogenes
homolog, the S. iniae protein is not observed in cultured supernatants, and mutants show no attenuation
in vivo suggesting a minor pathogenic role.

The streptolysin S cytolysin (SLS) of S. inaie is

homologous to that of S. pyogenes and contains hemolytic activity against erythrocytes, lymphocytes
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and neutrophils (102). Furthermore, expression of the S. iniae homolog in an S. pyogenes SLS mutant
restored hemolytic activity (181). Expression of the SLS locus appears to be controlled by the SivSR
two-component signal transduction system (TCS) (31). SivSR also regulates the cfi-encoded poreforming toxin CAMP factor (31), and has been shown in influence capsule production as well (30).
S. iniae produces a complex polysaccharide capsule that facilitates protection from
opsonophagocytic killing. The genes required for capsule biosynthesis are encoded in an operon of
approximately 21 kbp in size (185) that is transcriptionally controlled by the conserved CpsA
regulator, a member of the LytR_cpsA_psr family (117). Deletion of cpsA results in reduced capsule
biosynthesis and severe attenuation in vivo (185). The capsule operon was initially characterized
following transposon mutagenesis studies performed on two separate strains of S. iniae: strain 9117,
isolated from a human patient with bacteremic cellulitis (305), and strain NUF631, isolated from a
diseased Japanese flounder (Paralichtys olivaceus) (262).

Both studies reported that transposon

insertions affecting capsule production occurred within the same sets of genes: cpsH, orf276 and cpsM,
with one additional mutant in cpsK for 9117, suggesting either the importance of these genes in
capsule production or the amenability of these regions for transposon insertion. All capsule mutants
from strain NUF631 were shown to have decreased capsule production accompanied with decreased
survival in whole blood and macrophages (262). Mutants in either orf276 or cpsH of strain 9117
displayed a similar reduction in capsule production and increased susceptibility to killing in whole
blood (185, 202). In contrast, the cpsM mutant of strain 9117 displayed a significant increase in
capsule production with an accompanying increased survival in whole blood (185). Additionally, none
of the 9117 capsule mutants were found to be susceptible to macrophage-dependent killing (202). The
difference in macrophage susceptibility between 9117 and NUF631 is most likely due to strain
differences, as human isolates tend to be more virulent than those from fish (101); however the reason
for the inverse phenotypes related to mutations in cpsM is still unclear. CpsD has also been studied for
its role in capsule production, and mutants display similar phenotypes to those of cpsH, including
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reduced capsule production, sensitivity to cationic antimicrobial peptides and an increased
susceptibility to killing in whole blood (182).
S. inaie is a strong candidate for use as a model pathogen to study invasive streptococcal
disease. The prevention challenges, disease invasiveness and myriad of virulence determinants are
homologous to those observed with human streptococcal pathogens. The knowledge gained from
utilizing S. iniae as a model pathogen could enable direct comparison for use in control of human
streptococcal pathogens. Moreover, the use of a natural host such as the zebrafish to investigate
disease pathogenesis and infection control could be a powerful and cost-effective tool when fishing for
the ultimate therapeutic strategy.
Zebrafish as a biological model system. The zebrafish (Danio rerio) is a tropical freshwater
fish that has emerged as an important tool for biological studies. Their small size, relative low cost and
ease of breeding allows for studies to be performed in large scale. Zebrafish have been used for
studying diverse areas of biology including vertebrate development (46, 85, 219), aging (152),
cardiovascular disease (54), cancer (178, 223), neuroscience (141, 246) and toxicology (127, 176,
213).

Zebrafish have also proven to be a powerful tool for investigations into immune system

development, function and disease (197, 276). The zebrafish immune system is closely related to that
of humans, with both functional innate and adaptive arms (198, 208, 271, 276, 284-285). Zebrafish do
not have a fully functional adaptive immune system until around 4 to 6 weeks of development (167168), which offers a unique opportunity to study the functional role of innate immune components in
the absence of adaptive immunity. Moreover, with a complete sequenced genome, useful tools for
forward and reverse genetic techniques, gene silencing as well as inducible transgenics,

new

applications for this unique model organism are constantly emerging (6, 71).
Several technologies for genetic manipulation of the zebrafish make it a useful system for
disease investigation.

Gene silencing using morpholinos continues to be a valuable tool for

investigating gene function. Morpholinos are modified antisense oligos that are similar to DNA and
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RNA oligonucleotides, except that they have a morpholine rather than a ribose ring and are thus
extremely resistant to nucleases. Morpholinos are micro-injected into embryos and decrease or silence
expression of a specific target gene by either blocking translation initiation or inhibiting splicing (80,
86, 210). The generation of zebrafish mutants can be done by chemical mutagenesis using agents such
as ethylnitrosourea (ENU). Heterozygous germ line mutations for a specific phenotype can be mapped
by Targeting Induced Local Lesions in Genomes (TILLING) (79, 273). Additionally, retroviral or
transposon insertion libraries can be made by injecting retroviral constructs into blastula-staged
embryos, generating chimeric embryos in which clones of cells within the embryo contain different
insertions (5, 147). Insertions in cells that ultimately form the germ line are transmitted to the next
generation, and harvested sperm can be used to prepare genomic DNA for sequencing around the
insertion. Furthermore, technologies for using inducible transgenes have also been proven effective in
zebrafish. Tissue specific promoters can be used to drive expression of the reverse-Tet-controlled
transactivator (rtTA). In the presence of Doxycycline, the rtTA protein can then bind to a second
rtTA-responsive element to drive expression of a gene of interest or reporter gene, such as green
fluorescent protein (131). Alternatively the Cre/loxP system, which is traditionally used for the
generation of conditional mutants, has been used in zebrafish for transgene induction. In such a
system, tissue specific promoters drive expression of the Cre-recombinase, whereby a loxP-flanked
element within a promoter region is removed for reporter gene expression or expression of a gene of
interest (221). Additionally zebrafish larvae remain translucent for several weeks. Taking advantage
of this trait, zebrafish strains have been created in which macrophages and neutrophils express green
fluorescent protein, thus allowing for real-time imaging of the behavior of these cell types to various
stimuli in vivo (177). The ability to easily manipulate either the pathogen or the host for the study of
infectious disease, as well as real time imaging of disease progression could allow for unprecedented
insight into the host-pathogen interactions that occur during invasive infectious disease.
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The zebrafish has been a useful tool for the identification of streptococcal virulence genes
through large-scale mutagenesis of streptococcal pathogens. In separate signature-tagged mutagenesis
(STM) studies performed on S. iniae and S. pyogenes, 12 individually tagged STM vectors were used
to generate separate libraries from which individual mutants were pooled and injected into zebrafish
(153, 202).

At specific time points tissues were removed and screened by PCR for the

presence/absence of the specific mutants based on the individual STM tag. Mutations in genes
required for survival in the host were identified by the presence of the mutant in broth culture, but not
in tissue homogenates. This successful technique identified several novel streptococcal virulence
factors, and highlighted the importance of several previously characterized systems.
Zebrafish have also been used to investigate complex host/pathogen interactions involving
macrophage recruitment, granuloma formation and spread of Mycobacterium marinum. The ESX/RD1
secretion system locus of M. marinum was found to be involved in granuloma formation (296) through
the active recruitment of host macrophages to the expanding granuloma (75). The 6 kDa early secreted
antigen target (ESAT6) secreted by the RD1 locus was determined to induce production of matrixmetalloproteinase 9 (MMP9) in neighboring epithelial cells. The induction of MMP9 is what triggers
macrophage recruitment and granuloma expansion, which is critical for mycobacterial spread (297).
Virulence properties of several other pathogens have been studied using zebrafish infection models
including bacterial pathogens such as Salmonella typimurium (274), Pseudomonas aeruginosa (62,
230), Francisella sp. (295) and Edwardsiella tarda (236), as well as viral pathogens such as the
Infectious Spleen and Kidney Necrosis Virus (310) and Herpes Simplex Virus 1 (132).
Polymorphonuclear granulocytes.

Neutrophils, or polymorphonuclear leukocytes, are

extremely important for protection against microbial pathogens.

Neutrophils are professional

phagocytic cells which eliminate microbes through a variety of bactericidal mechanisms (256).
Patients with congenital neutropenia or chronic granulomatous disease, or who display increased
neutrophil destruction due to chemotherapy are at an increased risk for severe fungal and bacterial
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infections (191). Neutrophils are produced from myeloid precursors in the bone marrow in large
number and circulate in the blood stream at concentrations ranging from 3 to 6 million cells per ml in
healthy individuals (175). They are easily identified after Giemsa staining by their characteristic
multi-lobed nucleus and large concentration of cytoplasmic granules. The neutrophil granules contain
clusters of antimicrobial and cytotoxic substances that are delivered to the phagosome or to the exterior
of the cell during degranulation.
If microorganisms circumvent the physical barriers of the skin or mucous membranes,
neutrophils are rapidly recruited to the site of infection by responding to chemotatic signals produced
by neighboring cells and vascular endothelium nearest the infection site (243). Neutrophils escape
circulation through a series of sequential events that begin with initial weak “slow rolling” interactions
of selectins on both the neutrophil and activated vascular endothelial surfaces (308). This is followed
by firm adhesion to the endothelial surface through interactions involving neutrophil 2-integrins and
the endothelial immunoglobulin superfamily members Inter-cellular Adhesion Molecule (ICAM) -1
and ICAM-2. Strong adhesion triggers morphological changes for the neutrophil in preparation for
diapedesis. A collection of endothelial adhesion molecules including ICAM-1 and -2, Junctional
Adhesion Molecules (JAM), Endothelial cell Selective Adhesion Molecule (ESAM), and several
cadherins interact with similar molecules on the neutrophil cell surface to both assist in neutrophil
paracellular migration as well as stabilization of the endothelial cell junction. Neutrophils traverse the
basal membrane and tissues by breaking down the connective tissue with several enzymes including
elastases and matrix metallo proteinases (308).
Neutrophils in tissue display an increased phagocytic capacity compared to when in circulation
(267).

They also produce various chemokines for recruitment of additional inflammatory cells.

Neutrophils phagocytose and kill microbes through a complex series of events which begin with the
pathogen being engulfed into a early phagosomal vacuole (172).

Pathogens within the nascent
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phagosome are exposed to a burst of reactive oxygen species following assembly of the NADPH
oxidase. This is followed by a series of maturation events which involve a reduction of phagosomal
size and successive fusion of the pre-formed gelatinase, specific, and azurophilic granules (172, 256).
These granules deliver a diverse arsenal of bactericidal compounds including various antimicrobial
peptides, proteases and lysozyme in an attempt to eliminate the pathogen (98).
Neutrophils are also able to undergo a very specific type of programmed cell death (netosis)
that requires components of autophagy and the generation of superoxide, leading to the release of a
DNA/histone containing net-like extracellular trap (244). These neutrophil extracellular traps (NETs)
are able to contain invading pathogens in a mesh-like network to limit bacterial spread (37). Mass
spectrometry analysis of NETs reveals the association of 24 different cationic bactericidal proteins
within the NETs (288). NETs have been demonstrated to play a significant role in protection against
several pathogens including Leishmania amazonensis (112), Candida albicans (288), Aspergilis
fumigates (195) and Haemophilus influenzae (140). Several pathogens including S. pyogenes (56), S.
pneumoniae (204) and Staphylococcus aureus (23) have been shown to produce extracellular DNases
thought to dissolve NETs and promote bacterial spread.
Methionine and single carbon metabolism. The transfer of single carbon groups (i.e. methyl/
formyl groups) is an important chemical modification for compounds involved in a myriad of cellular
processes. These single carbon (C1) units are carried throughout the cell by tetrahydrofolate (THF), a
reduced form of folic acid. C1-THF derivatives are involved in single-carbon transfer reactions for the
synthesis of purines, formylmethionyl-tRNA, thymidylate, pantothenate, glycine, serine and
methionine (76, 190). Sulfonamides are antibacterial compounds that target the enzyme dihydrofolate
reductase (DHFR) involved in the synthesis of THF,

and are thus effective broad-spectrum

antimicrobials due to the variety of downstream pathways affected by THF deficiency (119).
THF primarily accepts methyl groups from serine, by the action of the serine
hydroxymethyltransferase (GlyA), or glycine, by the glycine cleavage complex (GCV), to form 5,10-
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methyleneTHF, which is the central compound in C1 metabolism (Fig. 1). 5,10-methyleneTHF can
either donate a C1 group directly for synthesis of thymidine nucleotides, be oxidized by NADP+ to
form 5,10-methenylTHF involved in purine nucleotide biosynthesis, or can be reduced by NADPH to
5-methylTHF for the biosynthesis of methionine (76).
Biosynthesis of methionine involves metabolic pathways for de novo biosynthesis of cysteine,
which is then converted to homocysteine through a cystathionine intermediate. The methyl group of 5methylTHF is transferred to homocysteine to form methionine by the action of either the cobalaminindependent methionine synthase (MetE) (82), or cobalamin-dependent methionine synthase (MetH)
and Vitamin B12 (16) (Fig. 1). Methionine is not only an important amino acid in translation and
protein synthesis, but is also the precursor for the synthesis of S-adenosylmethionine (SAM). SAM is
produced from methionine and adenosine-triphosphate (ATP) by the action of S-adenosylmethionine
synthase (MetK).

SAM is the primary methyl donor for transmethylation and transsulfuration

reactions, as well as polyamine synthesis (186). S-adenosylhomocysteine is formed as a reaction
product, and is rapidly converted back to homocysteine to be reused in the synthesis of methionine,
thus completing the methyl cycle.
Regulation of methionine biosynthesis has been best characterized in Gram negative organisms.
MetJ is a transcriptional repressor that binds excess SAM as a cofactor to repress transcription of the
de novo methionine biosynthesis genes when methionine levels are sufficient (Fig. 1) (169). This
transcriptional repression is relieved under sulfur limiting conditions when SAM levels drop and
methionine biosynthesis is required for synthesis of SAM (113).

Additionally, a LysR family

transcriptional regulator, MetR, utilizes homocysteine as a cofactor to compete with the MetJ:SAM
complex and increase methionine biosynthesis through transcriptional activation of metE and metF due
to a buildup of homocysteine (Fig. 1) (47, 65, 183, 234, 290-291). MetR also activates expression of
the GlyA serine hydroxymethyltransferase to increase synthesis of 5,10-methyleneTHF for
downstream use in methionie biosynthesis (234).
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Figure 1. Schematic of metabolic pathways associated with single-carbon (C1) unit flow. This
diagram represents possible outcomes for the C1-tetrahydrofolate (THF) derivatives, and how C1-THF
derivatives are used for biosynthesis of methionine and ultimately S-adenosylmethionine (SAM).
Only genes involved in metabolic processes discussed in the text are shown italicized in black. (SAM)
and (HC) indicate the transcriptional regulators MetJ and MetR utilize S-adenosylmethionine and
homocysteine as cofactors respectively. Solid arrows indicate enzymatic reactions, dashed arrows
represent transcriptional activation, and the dashed line indicates transcriptional repression.
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Apoptosis. Apoptosis is a natural pathway of programmed cell death that is utilized for
maintaining homeostasis, as part of the developmental process of multicellular organisms, and by the
immune system for removal of damaged or infected cells (316). Apoptosis can also be triggered under
conditions of cell stress such as DNA damage or increased generation of reactive oxygen species
(ROS). Activation of regulatory cascades leading to apoptosis occurs through both intrinsic and
extrinsic pathways in the cell. In the intrinsic pathway, various stimuli occurring from cell stress can
disturb the balance of Bcl-2 family proteins, which alter the mitochondrial transmembrane potential
leading to the release of cytochrome c into the cytosol (163). Cytochrome c in the cytosol initiates
activation of the apoptosome, which in turn triggers a signaling cascade resulting in the activation of
the cysteine-dependent aspartate-directed protease 3 (caspase 3). Caspase 3 is the terminal caspase of
the pro-apoptotic pathways and upon activation cleaves various targets to promote apoptotic death
(77). In the extrinsic pathway, ligands such as Fas (FasL) or tumor necrosis factor alpha (TNF) bind
to death receptors on the cell surface (253). Trimerization of bound receptors promotes recruitment of
various adaptor proteins that ultimately leads to the activation of caspase-8/10, triggering a cascade of
signaling events that leads to the activation of caspase 3 and subsequent apoptotic death . Apoptosis
must be tightly regulated to ensure that spontaneous activation of these catastrophic pathways does not
occur. Fas-induced apoptosis by the extrinsic pathway can be effectively blocked by proteins such as
the Flice-Inhibitory Protein (FLIP), while apoptosis triggered from the intrinsic pathway is inhibited by
stabilization of the mitochondrial membrane potential through Bcl-2 family proteins such as BclXL, or
by the cytokine response modifier A (CrmA). In addition, activation of caspase-3 by either pathway
can be blocked by inhibitor of apoptosis proteins (IAPs) such as XIAP, which bind directly to caspase
3 (122). Moreover, the protein kinase Akt can be activated by various growth factors to promote cell
survival through phosphorylation-inactivation of the pro-apoptotic protein Bad, along with activation
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of IKKa that ultimately leads to NFkB activation and subsequent expression of pro-survival genes such
as FLIP and BclXL (122).
Many bacterial pathogens have evolved different strategies to either induce or inhibit apoptosis
to promote their own survival (303). Pathogens such as Shigella, Salmonella, and Listeria have
evolved strategies to induce apoptosis of phagocytic cells in order to escape phagolysosomal killing
(105), while others such as Mycobacterium, Chlamydia, and Coxiella inhibit apoptosis using the
intracellular environment as a protective niche (187, 303). Bacterial pathogens that inhibit apoptosis
do so by a variety of strategies. E. coli K1 infection of murine macrophages results in expression of
the pro-survival gene BclXL and blockage of cytochrome c release (275), whereas Shigella flexneri
inhibits apoptosis in epithelial cells by directly blocking activation of caspase-3 (61).
S. agalactiae and S. pneumoniae-infected phagocytes have been shown to induce apoptosis by
48 hours post infection (287). In contrast, S. iniae (9117) has been shown to inhibit apoptosis in
macrophages 24 hours post infection (184). Furthermore, two different isolates of S. iniae (9033 and
173) resulted in the inhibition of apoptosis in primary fish phagocytes (281). The contrasting results
between S. pneumoniae, S. agalactiae, and S. iniae may be due to differences in the time points
investigated as well as the experimental conditions. Further studies are needed to determine the means
by which streptococcal pathogens affect host apoptotic pathways. Inhibition of the normal apoptotic
pathways would allow for prolonged intracellular survival, which could facilitate dissemination and
invasion into distant tissues.
Discovery of CpsY as a S. iniae virulence determinant. Initial studies into the transcriptional
regulation of the capsule operon of S. iniae revealed the presence of a second transcriptional regulator,
CpsY, which is inversely oriented upstream of cpsA and the capsule operon, separated by a shared
promoter region (Fig. 2) (185). CpsY was originally predicted to regulate capsule biosynthesis in S.
agalactiae due to its adjacent location to the capsule operon (156). Transcriptional reporter constructs
using either the cpsY or cpsA promoters controlling expression of the alkaline phosphatase gene
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revealed significantly reduced expression from both the cpsY and cpsA promoters in a mutant with an
in-frame-deletion of the cpsY gene (cpsY), suggesting that CpsY transcriptionally activates both itself
and the capsule operon (184). However, quantification of capsule biosynthesis by percoll gradient
centrifugation showed that the cpsY mutant had only slightly decreased levels of capsule compared to
wild type (185), indicating that CpsY has minimal effect on capsule biosynthesis. This was confirmed
by quantitative PCR where no difference in expression of the capsule operon was observed in the
cpsY mutant. Alkaline phosphatase promoter-reporter constructs for non-CpsY regulated promoters
were also found to have low expression in the cpsY mutant (personal observations), suggesting that
the observed dichotomy between qPCR, percoll gradient centrifugation and promoter-reporter results
may be due to the inherent inability of the cpsY mutant to effectively express the alkaline phosphatase
reporter, perhaps related to an uncharacterized toxicity of the gene product toward the cpsY mutant.
Infection of zebrafish by intramuscular injection of the cpsY mutant revealed a highly
attenuated phenotype with minimal invasion to the brain and decreased systemic survival (185).
Investigation into the regulation of cpsY showed that cpsY-promoter activity increased throughout
logarithmic growth phase when cultured in Todd-Hewitt yeast broth (ThyB), but not when cultured in
brain-heart infusion medium (BHI) (201). Immunohistochemistry of infected zebrafish revealed that
expression from the cpsY promoter was rapidly shut off upon injection into the muscle tissue and
remained off for the first 60 minutes post infection (p.i.); however, expression in the muscle tissue was
observed by 24 hours (201). In contrast, expression from the cpsY promoter was observed as early as
15 minutes p.i. in the heart and 30 minutes p.i. in the spleen (201). Furthermore, at these early time
points, expression appeared to occur only when the bacteria were localized intracellular in phagocytic
cells. Overall the data suggest that CpsY is tightly regulated and may play a role in intracellular
survival in vivo.
CpsY shares homology to the LysR family of transcriptional regulators (LTTR), which regulate
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Figure 2. Capsule synthesis operon map of S. iniae (accession no. AY904444). Bent arrows indicate
transcriptional promoter regions.
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the expression of genes with a wide array of functions (254). CpsY is highly conserved among the
streptococci, and homologs are found in both Gram positive and Gram negative species. CpsY
orthologs in Streptococcus mutans and S. agalactiae have been renamed MetR and MtaR respectively
due to their role in methionine transport and metabolism (259, 268), but evidence suggests that MtaR
has significant regulatory function unrelated to methionine metabolic processes as well (42). The
regulatory role CpsY has on methionine metabolic processes, as well as streptococcal virulence is the
major focus of this work and will be comprehensively discussed in the following chapters.
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CHAPTER 2
The Streptococcus iniae transcriptional regulator CpsY is required for protection
from neutrophil-mediated killing and proper growth in vitro.

Abstract
The ability of a pathogen to metabolically adapt to the local environment for optimal
expression of virulence determinants is a continued area of research. Orthologs of the Streptococcus
iniae LysR family regulator CpsY have been shown to regulate methionine biosynthesis and uptake
pathways, but appear to influence expression of several virulence genes as well. A S. iniae mutant
with an in-frame deletion of cpsY (cpsY) is highly attenuated in a zebrafish infection model. The
cpsY mutant displays a methionine-independent growth defect in serum, which differs from the
methionine-dependent defect observed for orthologous mutants of S. mutans and S. agalactiae. On the
contrary, the cpsY mutant can grow in excess of WT when supplemented with proteose peptone,
suggesting an inability to properly regulate growth. CpsY is critical for protection of S. iniae from
clearance by neutrophils in whole blood, but is dispensable for intracellular survival in macrophages.
Susceptibility of the cpsY mutant to killing in whole blood is not due to a growth defect because
inhibition of neutrophil phagocytosis rescues the mutant to WT levels. Thus CpsY appears to have a
pleiotropic regulatory role for S. iniae, integrating metabolism and virulence. Furthermore S. iniae
provides a unique model to investigate the paradigm of CpsY-dependent regulation during systemic
streptococcal infection.
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Introduction
Our understanding of the diverse repertoire of transcriptional signaling networks that
orchestrate optimal expression of virulence genes dependent upon the metabolic status of the cell is
quickly expanding (265, 313). Metabolic adaptations to the various environments encountered by a
pathogen within a host prove to be tremendously complex and under studied (87). Recent work on
streptococcal pathogens has revealed components of these regulatory pathways that relate the
nutritional status of the cell to control of growth phase and expression of virulence genes (3, 134, 145,
148, 192, 209, 272).
S. iniae is a major aquatic pathogen (88-89) that causes an invasive systemic infection with
severe bacteremia culminating in meningoencephalitis (4). Many instances of zoonoses have been
reported as a result of handling infected fish, typically resulting in a bacteremic cellulitis (95, 170,
305). The severity of an S. iniae infection is due in part to the ability to rapidly disseminate from the
site of infection through the blood stream and invade systemic tissues (185).

The complex

pathogenicity of S. iniae, and other systemic streptococcal pathogens, is reflected in the diversity of
genes that are critical to a successful infection (9, 142, 300). Several classical streptococcal virulence
factors have been shown to be important for the virulence of S. iniae, including the SivS/R-regulated
streptolysin S and CAMP factor (31, 181), as well as the major surface M protein (180). S. iniae also
contains a polysaccharide capsule that functions for protection from phagocytic clearance in whole
blood (182, 185, 202). Furthermore, several genes not previously studied for their virulence traits have
been shown to have critical roles during S. iniae infection of hybrid striped bass (HSB), including
phosphoglucomutase (pgmA) (45) and a novel polysaccharide deacetylase (pdi) (200).
We previously established the importance of a highly conserved LysR family transcriptional
regulator, CpsY, in a zebrafish infection model (185). Deletion of cpsY (cpsY) increased zebrafish
survival by 40% 4 days post-infection. Moreover, the cpsY mutant displayed a unique inability to
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disseminate to the brain within the first hour post-infection. CpsY was originally predicted to regulate
capsule biosynthesis in Streptococcus agalactiae due to its adjacent location to the capsule operon
(156). Further research determined that CpsY has little effect on capsule production in both S.
agalactiae (259) and S. iniae (185). Rather, CpsY was renamed MtaR in S. agalactiae (259) and MetR
in S. mutans (268) because of its influence on methionine biosynthesis and uptake. However, the
regulatory function of MtaR in S. agalactiae appears to extend beyond methionine metabolism (42).
In the present study, we define a critical role for CpsY during S. iniae systemic infection. We
show that CpsY is required for intracellular survival in neutrophils, but not macrophages, and that this
is critical for bacterial survival in whole blood. Furthermore, we discuss variations in the CpsYdependent regulation of methionine supply pathways that exist among streptococcal pathogens.
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Materials and Methods
Bacterial strains, media and culture conditions.

Streptococcus iniae 9117 is a human

clinical blood isolate from a patient with cellulitis (101). A mutant containing an in-frame deletion of
the cpsY gene used in this work was constructed previously (185). Streptococcal strains were routinely
cultured in Todd-Hewitt broth (BBL) supplemented with 0.2% yeast extract (BBL) (THY) in conical
tubes without shaking at 37 oC. For bacterial enumeration, serial dilutions were plated on THY agar
plates and incubated at 37 oC in 5% CO2. In all assays, overnight bacterial cultures were diluted 1:50
in fresh medium, and grown to mid-exponential phase (OD600 0.225) unless otherwise stated.
Bacterial growth curves. Overnight bacterial cultures were diluted 1:50 in 96-well plates
containing a 200 l total volume of THY or C medium (189), supplemented with either 400 g ml-1 Lmethionine (Sigma) or 2% proteose peptone #3 (BBL) when required. The plates were incubated at
37 oC in 5% CO2, and OD600 values were measured every 30 min using a VersamaxTM microplate
reader (Molecular Devices).
Growth assays in human serum were performed as previously described for Streptococcus
agalactiae (259).

Briefly, non-heparinized blood was obtained from human volunteers by

venipuncture, allowed to clot and centrifuged at 1000 x g for 5 min. Mid-exponential phase cultures of
S. iniae strains grown in THY were collected by centrifugation, washed 2 times in phosphate buffered
saline (PBS, Invitrogen) and diluted to 1 x 105 CFU ml-1 in PBS. Ten microliters of diluted bacteria
was added to 1 ml of DMEM with 50% human serum in a 1.5 ml microcentrifuge tube, supplemented
with 400 g ml-1 L-methionine (Sigma) when required. Tubes were incubated at 37 oC with gentle
rotation. At the indicated time points, bacterial growth was determined by serial dilution on THY agar.
Zebrafish infections.

Groups of 6 zebrafish (Danio rerio) adults were infected by

intramuscular (i.m.) injection into the dorsal muscle with either S. iniae WT or the cpsY mutant from
mid-exponential phase cultures as previously described (215). A 30-gauge needle was used to inject
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10 l of a 1 x 107 CFU ml-1 bacterial suspension in PBS for an infectious dose of 1 x 105 CFU.
Zebrafish were euthanized with a lethal dose of Ethyl 3-aminobenzoate methanesulfonate (Tricaine,
Sigma) at the indicated time point, and specific organs were harvested and gently homogenized in 300
l PBS. One hundred microliters of the homogenate was loaded into a cytology funnel (Thermo),
centrifuged onto glass slides for 3 min at 700 rpm in a Cytospin 1 centrifuge (Shandon Elliott) and
stained using the HEMA 3 stain set (Fisher Scientific). Slides were viewed and documented with an
Axioskop 40 microscope (Carl Zeiss, Inc.) fitted with an AxioCam MRc camera.
RNA isolation and quantitative polymerase chain reaction (qPCR).

Bacteria were

subcultured to logarithmic phase or early stationary phase in either THY or THY supplemented with
2% proteose peptone #3 (TP). When required, 4 mM L-methionine (Sigma) or homocysteine (Sigma)
was added for 30 min upon reaching the appropriate growth phase. Five milliliters of culture was
centrifuged and resuspended in 1 ml phosphate buffered saline (PBS) with 25 mg ml-1 lysozyme
(Sigma) and 50 U of mutanolysin (Sigma). Following 30 min incubation at 37 oC, the bacteria were
centrifuged, resuspended in 1 ml Trizol (Sigma) and incubated at room temperature for 5 min. Two
hundred microliters of chloroform was added to the suspensions, mixed vigorously and incubated an
additional 3 min at room temperature. The preparations were centrifuged 13,000 x g at 4 oC for 15
min.

The aqueous phase was transferred to a fresh microcentrifuge tube, mixed with 500 l

isopropanol and incubated 10 min at room temperature. The samples were centrifuged 13,000 x g at 4
o

C for 15 min, washed twice with 70% ethanol, and resuspended in 100 l of water. Contaminating

DNA was digested with 5 g of DNaseI (Qiagen) at 37 oC for 2 hrs, and RNA was purified using the
RNeasy® MinEluteTM cleanup kit (Qiagen). For isolation of macrophage RNA, infected or mocktreated cells were washed twice in PBS, and RNA was collected using the SV total RNA isolation kit
(Promega) per manufacturer instructions.
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For qPCR reactions 100 g of total RNA was combined in 20 l total reaction volumes with
0.2 M forward and reverse primers, Express SYBR® GreenERTM (Invitrogen) and Express
SuperScript® Mix (Invitrogen) per manufacturer instructions. Primer sequences for transcriptional
analysis of S. iniae were as follows: recA fwd 5’-CTCAGGTGCTGTTGATTTGG-3’, recA rev 5’TGCAGAGAGTTTACGCATGG-3’; atmB fwd 5’-CCCGTTGGGATAAAATTGAA-3’, atmB rev 5’CACCATTTGCAACTGCCTTA-3’.

Primer sequences for transcriptional analysis of infected

macrophages were as follows: -actin fwd 5’-TAAAACGCAGCTCAGTAACAGTCCG-3’, -actin
rev 5’- TGGAATCCTGTGGCATCCATGAAAC-3’; FLIP fwd 5’-CGTCTCCTGCCTTGCTTCAG3’, FLIP rev 5’-CGAACCCAGACACTGCACAA-3’; XIAP fwd 5’-CTGAGTATATCCATGTCC-3’,
XIAP rev 5’-ATGCAGAATGGTCAGTAC-3’; BclXL fwd 5’-TTCGGGATGGAGTAAACTGG-3’,
BclXL rev 5’-TGCAATCCGACTCACCAATA-3’; Bax fwd 5’-CCCCAGTTGAAGTTGCCATC-3’,
Bax rev 5’-GTTTCATCCAGGATCGAGCAG-3’. Reactions were performed in triplicate using a
BioRad iCyclerTM with the following cycling conditions: 5 min at 50 oC, 2 min at 95 oC, 40 cycles of
15 sec 95 oC and 1 min 60 oC. Melting curves were performed after completion of each experiment.
Relative fold change in gene expression was calculated by 2-(CT), where CT is [CT(target gene) CT(recA)]mutant - [CT(target gene) - CT(recA)]wild type, CT being the threshold cycle.
Sequence alignment. S. iniae genomic sequence data was obtained from Human Genome
Sequencing Center at Baylor College of Medicine. Sequences for the CpsY orthologs MtaR of S.
agalactiae A909 (YP_329877), MetR of S. mutans UA159 (AAN58910), CpsY of S. pyogenes
(NP_269094) and CpsY of S. iniae (AAY17292), as well as the nucleotide promoter sequence
immediately upstream of atmB (metQ1) of S. agalactiae A909 (YP_330257), S. mutans UA159
(AAN59551) and S. pyogenes (NP_268657) were obtained from GenBank. Sequences were aligned
and plotted using ClustalX through the Mobyle portal (http://mobyle.pasteur.fr/cgi-bin/portal.py)
(216).
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Macrophage adherence, internalization and survival assays.

The RAW 264.7 murine

macrophage cell line (242) was maintained in 75 cm2 cell culture flasks (Corning) in Dulbecco’s
Modified Eagle’s Medium (DMEM; Gibco) containing 10% heat-inactivated fetal bovine serum (FBS;
Gibco) at 37 oC with 5% CO2. Macrophage infection assays were performed in 24 well flat bottom
plates (Greiner bio-one). One day prior to each assay, macrophages were seeded at a density of 0.5 x
106 cells per well in 1 ml DMEM with 10% FBS medium. When required, macrophages were
activated with 100 U ml-1 of murine IFN- at 1.5 hr post-seeding. After overnight incubation, cell
culture medium was removed and macrophages were washed 3 times with PBS. Mid-exponential
phase bacteria were diluted 1:100 into 1 ml DMEM with 10% FBS medium, which was then added to
cells at an MOI of 1 (bacteria:cells). The plates were centrifuged for 5 min at 250 x g to allow for
contact between bacteria and the cell monolayer. After 1 hr, cell culture medium was removed, and
macrophages were washed 5 times with 1 ml of PBS for removal of any non-adherent bacteria. For
adherence assays, the cells were lysed in 1 ml sterile ddH2O and 100 l was serially diluted and plated
on THY agar for enumeration of bacterial CFU, which represents both adhered and internalized
bacteria. For internalization and survival assays, infected cells were incubated with 1 ml fresh DMEM
with 10% FBS containing 100 g ml-1 gentamicin (Gibco) for 1 hr to kill all extracellular bacteria.
After the 1 hour incubation, cells were washed 3 times with PBS. For internalization assays, cells were
lysed in 1 ml sterile ddH2O and 100 l was removed, serially diluted and plated on TP agar for
enumeration of surviving intracellular bacteria. For survival assays, 1 ml of fresh DMEM with 10%
FBS was added, which was then considered to be the 0 hr time point. At specified times supernatants
were collected, cells were washed 3 times in PBS and lysed in 1 ml sterile ddH2O. One hundred
microliters of supernatants and lysates were serially diluted and plated on THY agar for enumeration
of bacterial CFU.

Final adherence numbers were calculated by (adhered: internalized CFU) –
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(internalized CFU). All infections were performed in duplicate and each experiment was repeated 3
times.
Fluorescent microscopy for macrophage viability. To assess cell viability, macrophage
infections were carried out as described above except circular glass coverslips were placed in each well
prior to macrophage seeding. At specified time points, culture medium was removed and cells were
gently washed 3 times in 1 ml sterile 0.9% NaCl. The LIVE/DEAD® BacLightTM kit (Invitrogen) was
used to visualize cell viability per manufacturer’s instructions. Briefly, 1 ml of 0.9% saline with 3 l
of an equal mixture of SYTO 9 dye and propidium iodide was added to the cells in the 24 well plate,
and incubated at room temperature in the dark for 15 minutes. The coverslips were then carefully
removed from the wells and gently placed cell side up onto glass microscope slides, immersed in
BacLightTM mounting oil, and covered with a final glass coverslip. Prepared slides were photographed
by fluorescence microscopy using an Axioskop 40 microscope (Carl Zeiss, Inc.) fitted with an
AxioCam MRc camera.
Macrophage apoptosis assay. Macrophages were infected as above with either live bacteria
or culture supernatants collected from growth during mid-logarithmic phase. Culture supernatants
were filtered through an 0.2 micrometer filter, and either fractioned using a 50 kDA or 100 kDa cutoff
centrifugal filter unit (Amicon) or treated with 1 mg ml-1 proteinase K (Sigma) in 10 mM Tris Hcl, pH
7.5 buffer for 2 hr at 37 oC when required. At 21 hr post-infection, 0.3 M staurosporine (Sigma) or 1
M camptothecin (Sigma) was added for 3 hr to induce apoptosis. At 24 hr post-infection induction of
apoptosis was determined by measuring caspase 3 activity using the EnzChek Caspase 3 Assay Kit # 2
(Invitrogen/Molecular Probes) per manufacturer instructions.
Whole blood survival.

Heparinized human whole blood was collected by venipuncture.

When required, cytochalasin D (Sigma) was added to a final concentration of 10 g ml-1 30 min. prior
to incubation with bacteria. Mid-exponential phase bacterial cultures were adjusted to 1 x 104 CFU ml-
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1

, inoculated 1:100 in 1 ml whole blood, and incubated for 3 hours at 37 °C with gentle rotation. One

hundred microliters was serially diluted and plated on THY agar for enumeration of bacterial survival.
All infections were performed in duplicate and each experiment was repeated 3 times.
Neutrophil infections. Human polymorphonuclear leukocytes, or neutrophils, were isolated as
follows. Heparinized human whole blood was collected by venipuncture and mixed in equal volume
with 3% dextran (MP Biomedicals) in saline using 50 ml conical tubes. Red blood cells were allowed
to sediment out and the supernatant was centrifuged for 10 min at 800 x g at 4 oC to pellet the
remaining cellular fraction. Pellets were resuspended in 35 ml 0.9% NaCl and a 10 ml underlay of
Ficoll-Paque (GE Healthcare) was applied. This was centrifuged for 30 min at 410 x g in a hanging
bucket rotor at room temperature to separate out the granulocyte fraction. The supernatant was gently
aspirated down to the loose pellet of granulocytes and erythrocytes. Remaining erythrocytes were
lysed by resuspension of the pellet with 10 ml sterile H2O for 28 seconds and isotonicity was quickly
restored with 10 ml 1.8% NaCl. Purified neutrophils were pelleted by centrifugation at 500 x g and
resuspended in 3 ml DMEM. Neutrophil concentration was determined by hemocytometer count.
For infections, neutrophils were diluted to a final concentration of 1 x 106 cells ml-1 in DMEM
with 50% human serum. When required, neutrophils were pretreated 30 min prior to addition of
bacteria with 10 g ml-1 cytochalasin D (Sigma) at 37 oC with gentle rotation. For experiments
requiring heat-inactivated serum, human serum samples were incubated at 55 oC for 30 min prior to
neutrophil addition. Mid-exponential phase cultures were washed twice in PBS and diluted to 1 x 105
CFU ml-1 in PBS. Ten microliters was inoculated into a 1 ml neutrophil suspension or media alone
using 1.5 ml microcentrifuge tubes. Samples were incubated at 37 °C for 3 hr with gentle rotation.
One hundred microliters of the sample was serial diluted and plated on THY agar for enumeration of
bacterial survival. In parallel, 100 l of the same sample was loaded into a cytology funnel (Thermo),
centrifuged onto glass slides for 3 min at 700 rpm in a Cytospin 1 centrifuge (Shandon Elliott) and
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stained using the HEMA 3 stain set (Fisher Scientific). Slides were viewed with an Axioskop 40
microscope (Carl Zeiss, Inc.) fitted with an AxioCam MRc camera.
Statistical analysis. A statistical analysis for all functional tests was performed by two-tailed
Student's t test using StatView analysis software.
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Results
CpsY influences growth in vitro.

Previous work demonstrated that disruption of the CpsY

ortholog MtaR in S. agalactiae results in a significant growth defect in human plasma that can be
rescued with excess methionine (42, 259). To determine if this same phenotype existed in S. iniae,
both the WT and the cpsY mutant were cultured in human serum supplemented with and without 400
g ml-1 L-methionine. Growth of the cpsY mutant paralleled that of WT for the first 3 hours in serum
alone, after which a significant drop in the growth rate resulted in approximately 1.5 log fewer CFU
ml-1 recovered by 6 hr (Fig 3). This attenuation could not be rescued with excess methionine. The
additional methionine had no influence on the growth of WT S. iniae consistent with previous reports
for S. agalactiae (259).
To determine whether this same methionine-independent growth attenuation of the cpsY
mutant translated to other media, growth was examined in THY both, a complex medium containing
neopeptone, beef heart infusion, yeast extract and dextrose as a carbon source. In this medium, the
cpsY mutant exhibited a similar pattern to growth in serum, demonstrating a significant drop after 3
hrs, which was independent of methionine (Fig. 4A). However when cultured in C-medium, a medium
containing yeast extract and 0.5% proteose peptone 3 but no dextrose, the cpsY mutant grew identical
to WT (Fig. 4B). This identical growth pattern was due to a decrease in cell density at stationary phase
of the WT in C-medium compared to THY, and not due to an enhancement in the growth of the cpsY
mutant. Again, the addition of excess methionine had no effect on growth of either WT or the cpsY
mutant. Because C-medium contains proteose peptone 3, we supplemented THY broth with 2%
proteose peptone #3 and monitored growth of WT and the cpsY mutant. Adding peptone drastically
extended exponential growth of the cpsY mutant reaching a final cell density over 2.5 times greater
than without peptone (Fig 5A). This was contrasted by the minimal change in growth observed for
WT S. iniae in the presence of peptone (Fig. 5A). A similar trend was observed for growth of the two
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Figure 3. Serum growth curves. Mid logarithmic phase cultures of S. iniae WT along with the cpsY
mutant were diluted into 1 ml DMEM 50% human serum with (+) or without 400 g ml-1 Lmethionine. Samples were incubated at 37 oC and bacterial CFU were determined at the indicated time
points by serial dilution and plating on THY. Error bars represent  standard error. *p < 0.05
compared to WT.
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Figure 4. Effect of methionine on bacterial growth. Overnight cultures of S. iniae WT and the cpsY
mutant were diluted 1:50 into 200 l of THY (A) or C-medium (B). When required, medium was
supplemented with 400 g ml-1 L-methionine (+). Samples were incubated at 37 oC and OD600
measurements were recorded every 30 min. A representative experiment is shown. Error bars
represent  standard error. *p < 0.05 compared to WT.
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Figure 5. Effect of proteose peptone on bacterial growth. Overnight cultures of S. iniae 9117 WT and
the cpsY mutant were diluted 1:50 into 200 l of THY (A) or C-medium (B). When required, the
medium was supplemented with 2% proteose peptone #3 (+). Samples were incubated at 37 oC and
OD600 measurements were recorded every 30 min. A representative experiment is shown. Error bars
represent  standard error. *p < 0.05 compared to WT.
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strains in C-medium although growth phenotypes were not as severe (Fig. 5B). This suggests that WT
S. inaie can manage the excess nutrients supplied in peptone with minimal effect on normal growth
patterns, whereas the cpsY mutant displays a type of unrestrained exponential growth. Overall the
data indicate that CpsY influences the growth patterns of S. iniae in a methionine-independent manner.
CpsY regulation of methionine metabolic pathways. The S. iniae CpsY protein shares 79%
amino acid sequence identity to the orthologs MtaR of S. agalactiae and MetR of S. mutans. Both
MtaR and MetR have been shown to regulate genes involved in methionine biosynthesis and uptake
(259, 268). Thus we hypothesized that the insensitivity to methionine on growth of the cpsY mutant
may be due to differences in these metabolic pathways. To address this hypothesis the genomes of S.
iniae and several other streptococcal species were examined by BLAST analysis for the presence of
genes involved in the biosynthesis and uptake of methionine as previously described for S. mutans
(Fig. 6) (268). Neither S. iniae nor S. agalactiae possess the full complement of genes required for denovo methionine biosynthesis from cysteine (Table 1); however, all streptococcal species investigated
were found to contain the AtmBDE (MetQ1NP) methionine transport system.

Additionally, S.

agalactiae contains the genes encoding MetE and MetF for conversion of homocysteine to methionine.
S. iniae does not possess metE or metF, and thus appears to be purely auxotrophic for methionine.
The methionine-dependent growth defect of the S. agalactiae mtaR mutant was attributed to the
inability to effectively transport exogenous methionine due to reduced expression of the MetQ1NP
methionine transport system (42, 259). Although exogenous methionine could not rescue growth of
the S. iniae cpsY mutant (Fig. 4), the role of CpsY in regulation of the AtmBDE locus was still in
question. Quantitative PCR (qPCR) was performed to assess CpsY-dependent regulation of the atmB
gene under various growth conditions. When cultured in THY broth to either mid-logarithmic or
stationary phase, there was < 2 fold change in gene expression for the cpsY mutant relative to WT
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Figure 6. Schematic of streptococcal methionine biosynthesis and uptake pathways. The pathways
represented were previously characterized for S. mutans (50). Genes present in S. iniae as determined
by BLASTP analysis are shown in black, while genes absent are in grey. Gene designations are listed
in Table 1.
SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SRH, Sribosylhomocysteine; MET, Methionine; AI2, Autoinducer 2.
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Table 1. Orthologs of the methionine metabolism and transport pathways.
Gene
Function
Sina Spya Saga
Serine acetyltransferase
+
+
+
cysE
Cysteine synthase
+
+
+
cysK
0
0
0
metI
Cystathionine -synthase
+
+
+
metC
Cystathionine -lyase
Homoserine O-succinyltransferase
0
0
0
metB
O-acetylhomoserine sulfhydrylase
0
0
0
metY
Methionine synthase
0
0
+
metE
5,10-methylenetetrahydrofolate reductase 0
0
+
metF
S-adenosylmethionene synthase
+
+
+
metK
Methylthioadenosine nucleosidase
+
+
+
pfs
S-ribosylhomocysteinase
+
+
+
luxS
ABC transporter, Substrate binding protein +
+
+
atmB
ABC transporter, ATP binding protein
+
+
+
atmD
ABC transporter, Permease
+
+
+
atmE
a

Smua
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Species designations are as follows: Sin, Streptococcus iniae 9117; Spy, Streptococcus pyogenes M1
GAS; Sag, Streptococcus agalactiae A909; Smu, Streptococcus mutans UA159. Symbol designations
are (+) for the presence or (0) for absence of the gene as determined by BLASTP using genes
previously identified in S. mutans.
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Table 2. Relative atmB expression for cpsY
Growth Phase
atmBN relative to WTb
Mediaa
THY
mid logarithmic
0.585 ± 0.17
THY
stationary
1.154 ± 0.14
THY + MET
mid logarithmic
0.349 ± 0.03
THY + HC
mid logarithmic
1.302 ± 0.03
THY + MET
stationary
0.288 ± 0.05
THY + HC
stationary
0.857 ± 0.04
TP
mid logarithmic
2.607 ± 0.49
TP
stationary
1.280 ± 0.53
a
b

Addition of 4 mM L-methionine (MET) or homocysteine (HC) for 30 min.
Relative fold change (N) as determined by the CT method.
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(Table 2). However, addition of 4 mM exogenous methionine for 30 min at mid-logarithmic or
stationary phase resulted in a relative decreased expression of over 2.5 and 3.5 fold respectively. This
suggests that CpsY is a transcriptional activator of atmB in the presence of methionine. Addition of
exogenous homocysteine, however, had minimal effect on atmB gene expression. In contrast to these
observations, addition of 2% proteose peptone (TP) resulted in 2.5 fold increased expression of atmB
relative to WT during mid-log phase, but not stationary phase.

Thus CpsY functions as a

transcriptional activator of atmB in the presence of exogenous methionine; however, the presence of
proteose peptone disrupts this regulation, suggesting other regulatory elements may be involved.
Transcriptional control of atmB by CpsY orthologs is proposed to occur through interactions
with a specific promoter element termed the Met box (42, 248, 268). Sequence alignment of the atmB
promoter region in S. iniae to several other streptococcal species revealed the presence of a Met box in
the same position upstream of the predicted -10, -35 sites (Fig. 7). Overall the data are concurrent with
the proposed regulation of the AtmBDE methionine transporter for other streptococcal species.
However, this regulation does not explain how CpsY influences S. iniae growth given that exogenous
methionine does not rescue the cpsY mutant in vitro. Thus, CpsY may have pleiotropic effects on S.
iniae that extend beyond regulation of methionine metabolism, which has also been suggested for S.
agalactiae (42).
CpsY facilitates S. iniae tissue specific localization within macrophages. During previous
studies of S. iniae, CpsY was found to be essential for systemic infection in a zebrafish model (185).
Whereas wild type (WT) S. iniae could disseminate rapidly to the brain following intramuscular
injection, the cpsY mutant displayed an inability to efficiently spread beyond the spleen (185). Thus,
we sought to determine a more specific function for CpsY during the course of systemic infection.
Adult zebrafish were infected with WT S. iniae or the cpsY mutant by intramuscular injection, and
systemic organs were harvested 24 hr post-infection for histological analysis. Visual examination of
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Figure 7. Promoter alignment for the atmBDE cluster. Sequences obtained from GenBank were
aligned and plotted using ClustalX. The previously determined S. mutans transcriptional start site (50)
is in bold, predicted -10 and -35 sites are underlined, translational start codon is italicized, and
predicted Met boxes are shaded. Sag, S. agalactiae A909; Spy, S. pyogenes M1; Sin, S. iniae 9117;
Smu, S. mutans UA159.
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Figure 8. Images of tissue homogenates from S. iniae-infected zebrafish. Zebrafish were injected i.m.
with 105 CFU of either S. iniae WT or the cpsY mutant. Zebrafish spleens (A) or brains (B) were
dissected 24 hours post-infection, gently homogenized in PBS, cytocentrifuged on to glass slides and
stained for visualization. Two representative images for each condition are shown. Black arrows
depict examples of intracellular bacteria within macrophages. Macrophage nuclei are noted with a
white asterisk.
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HEMA-stained cytospin preparations from spleen homogenates showed that both WT and the cpsY
mutant were contained within macrophage phagosomal compartments (Fig. 8A). For all infected fish
(n = 6), the majority of splenic macrophages were filled with cocci with few extracellular bacteria
observed. In contrast, only WT could be detected in cytospin preparations of brain homogenates (Fig.
8B). Brain macrophage-like cells from cpsY-infected fish showed signs of activation with large
empty phagosomal vacuoles, but contained no bacteria (Fig. 8B).

These results suggest that S. iniae

localizes within tissue macrophages during the course of systemic infection, and that CpsY affects this
localization within specific tissue environments.
Intracellular survival in macrophages is independent of CpsY. Because of the tissue
specific macrophage localization observed in the zebrafish infection model, we sought to determine if
S. iniae intracellular survival in macrophages was dependent upon CpsY. The RAW 264.7 murine
macrophage cell line (242) was used as an in vitro platform to evaluate streptococcal-macrophage
interactions. Macrophages were infected with either WT S. iniae or the cpsY mutant for 1 hr to allow
for bacterial uptake, followed by a 1 hr gentamicin treatment to kill all extracellular bacteria. Bacterial
growth was then determined at various time points over the following 24 hrs. No significant difference
was observed between S. iniae WT and the cpsY mutant in macrophage cell lysates (Fig. 9A) or
culture supernatants (Fig. 9B) at all time points tested. The number of bacteria remained relatively
constant at the 2 and 4 hour time points, and by 24 hr had increased over 3-logarithms. Adherence and
internalization assays also revealed no significant difference in bacterial uptake by macrophages (Fig.
9C).

Furthermore, macrophage activation by pretreatment with IFN- resulted in no significant

difference from untreated samples (Fig. 9). S. iniae does not appear to be actively killing macrophages
because viability staining of infected macrophages showed the majority of macrophages to be alive,
intact and filled with bacteria through 48 hr (Fig. 10). Overall these results indicate that CpsY does not
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Figure 9. S. iniae macrophage infections. Raw 264.7 macrophages were infected at an M.O.I. of 1
with WT (grey bars) or cpsY (white bars) as described in materials and methods. At required time
points culture supernatants were collected, cells were washed, and lysed in H2O. Dilutions of the cell
lysates (A) and culture supernatants (B) were serially diluted and plated for bacterial CFU. For certain
experiments, macrophages were activated by pretreatment with 100 U ml-1 of murine IFN- () for 24
hr prior to infection with bacteria. (C) Adherence (A) and internalization (I) assays were performed as
described in materials and methods. Error bars represent  standard error.
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cpsY

4 hr
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48 hr

Figure 10. Live/Dead® fluorescent staining of S. iniae-infected macrophages. RAW 264.7
macrophages were infected with S. iniae WT or cpsY as described in materials and methods. At the
indicated time points, cells were washed with 0.9% NaCl, and assayed for macrophage viability using
the LIVE/DEAD® BacLightTM kit (Invitrogen) per manufacturer’s instructions. White asterisk
indicates the macrophage nucleus, and white arrows indicate S. iniae.
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play an essential role during interactions with macrophages in vitro, and suggest an alternative role in
S. iniae pathogenesis.
Bacterial

pathogen-associated

molecular

patterns

prevent

chemically-induced

macrophage apoptosis in vitro. Because S. iniae-infected macrophages remain viable though 48 hr
post-infection, we sought to determine if this viability was a specific manipulation of the macrophage
toward a pro-survival response, or if S. iniae simply was not actively killing the macrophage.
Macrophages were infected as above for 24 hr, and assayed for the induction of apoptosis by
measuring caspase 3 activity. Macrophages infected with either S. iniae WT or the cpsY mutant
displayed minimal caspase 3 activity over mock-infected cells at 24 hours post-infection (Fig. 11),
indicating that S. iniae does not induce apoptosis of macrophages. To determine whether S. iniae
actively manipulates macrophages to protect against apoptosis, infected cells were treated with either 3
M camptothecin (CAM) or staurosporine (STA) to induce apoptosis. Mock-infected macrophages
displayed a characteristic induction of caspase 3 activity in the presence of either inducer (Fig. 11). In
contrast, CAM or STA-treated macrophages infected with either WT or the cpsY mutant showed no
caspase 3 activity above background level (Fig. 11). The data suggest that S. iniae-infection of
macrophages promotes a pro-survival response independent of CpsY, which can override the proapoptotic induction signals provided by CAM and STA. Quantitative PCR of S. iniae WT-infected
macrophages revealed an increased expression of the pro-survival factors BclXL and FLIP, but a
decreased expression of XIAP relative to mock treated macrophages (Fig. 12). BclXL and FLIP act on
components associated with the initial induction of apoptosis signaling cascades, while XIAP acts to
directly inhibit caspase 3. The data suggest that S. iniae induces a macrophage pro-survival response
of specific apoptosis-related pathways upstream of caspase 3 activation.
To assess whether the macrophage pro-survival state was induced by an S. iniae secreted factor,
macrophages were pre-treated for 24 hr with filtered culture supernatants (0.2 micron filter) from mid-
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Figure 11. Macrophage apoptosis. RAW 264.7 macrophages were infected with S. iniae WT, cpsY
or mock infected as described in materials and methods. At 21 hr post-infection cells were treated with
0.3 M staurosporine (STA, light grey bars), 1 M camptothecin (CAM, dashed grey bars) or left
untreated (black bars) for 3 hr to induce apoptosis. At 24 hr post-infection induction of apoptosis was
determined by measuring caspase 3 activity using the EnzChek Caspase 3 Assay Kit # 2 (Invitrogen).
RFU, relative fluorescence units.
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Figure 12. qPCR of S. iniae-infected macrophages. RAW 264.7 macrophages were infected with WT
S. iniae and total RNA was isolated after 24 hours. Relative fold change gene expression compared to
mock infection was determined by the 2-CT method.
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logarithmic phase growth, then treated with STA and assayed for caspase 3 activity as before. As
observed with live cells, S. iniae culture supernatants were also able to provide protection against
STA-induced apoptosis (Fig. 13), suggesting that the pro-survival inducing factor is either actively
secreted or is released from the outer surface of the cell during growth. Using centrifugal filter units to
fractionate the culture supernatants, the pro-survival inducing factor was determined to be > 100 kDa
in size (Fig. 13). A slight reduction in STA-induced caspase 3 activity was observed in the fraction <
100 kDa suggesting that this factor may be a polymeric substance with subunits < 100 kDa (Fig. 13).
A secreted or released substance of that size could be a large protein complex attached to the cell wall
such as a pilus, or possibly related to the polysaccharide capsule. To determine whether capsule was
responsible for this phenomenon, the same macrophage treatments were performed with either live
bacteria or filtered culture supernatants from both WT S. iniae and a cpsA-insertional mutant, which
contains a defect in capsule production (185). Macrophages treated with the cpsA-insertional mutant
displayed no difference from WT treatment indicating that capsule was not involved (Fig. 14). Similar
observations occurred when culture supernatants were pre-treated with proteinase K to remove any
proteins (Fig. 14). Thus the pro-survival inducing factor appears to be a large proteinase K-resistant
polymeric substance unrelated to capsule. This prompted examination of culture supernatants from a
variety of other Gram positive and Gram negative bacteria to determine if this factor was a shared
substance from all microorganisms such as peptidoglycan. Treatment of macrophages with filtered
culture supernatants from S. iniae, S. aureus, Escherichia coli, Vibrio cholerae, Lactococcus lactis and
S. agalactiae, as well as live E. coli was able to prevent STA-induced apoptosis (Fig. 15). The data
indicate that the observed macrophage pro-survival response is not specific to S. iniae, but rather is a
programmed macrophage response to the presence of microorganisms under these conditions.
CpsY is essential for S. iniae survival in whole blood. Systemic dissemination from the
initial infection site requires a pathogen to effectively enter and survive in the blood stream. While in
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Figure 13. Macrophage apoptosis of S. iniae culture supernatant-treated cells. S. iniae mid-log phase
culture supernatants grown in THY were filtered on an 0.2 M filter, and fractioned using a 50 kDA or
100 kDa cutoff centrifugal filter unit. RAW 264.7 macrophages were either infected with WT S. iniae
as before, treated with the filtered culture supernatants (S) or mock infected for 24 hours as described
in materials and methods. At 21 hr post-infection cells were treated 3 hr with 0.3 M staurosporine
(STA, light grey bars) to induce apoptosis or left untreated (black bars). At 24 hr post-infection
induction of apoptosis was determined by measuring caspase 3 activity using the EnzChek Caspase 3
Assay Kit # 2 (Invitrogen). RFU, relative fluorescence units.
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Figure 14. Macrophage apoptosis. RAW 264.7 macrophages were infected with either WT S. iniae or
a capsule-deficient mutant (cpsA), or treated with culture supernatants (S) from either strain for 24
hours as before. Additionally WT S. iniae supernatants were treated with proteinase K (ProK) for 3
hours prior to macrophage treatment. At 21 hr post-infection, cells were treated for 3 hr with 0.3 M
staurosporine (STA, light grey bars) to induce apoptosis or left untreated (black bars). At 24 hr postinfection induction of apoptosis was determined by measuring caspase 3 activity using the EnzChek
Caspase 3 Assay Kit # 2 (Invitrogen). RFU, relative fluorescence units.
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Figure 15. Macrophage apoptosis of cells treated with culture supernatants from a panel of bacteria.
RAW 264.7 macrophages were treated with mid-logarithmic phase filtered culture supernatants for 24
hours as before. At 21 hr post-treatment cells were treated for 3 hr with 0.3 M staurosporine (STA,
light grey bars) to induce apoptosis or left untreated (black bars). At 24 hr post-infection induction of
apoptosis was determined by measuring caspase 3 activity using the EnzChek Caspase 3 Assay Kit # 2
(Invitrogen). RFU, relative fluorescence units. Sin, Streptococcus iniae; Sau, Staphylococcus aureus;
Eco, Escherichia coli; Vch, Vibrio cholerae; Lla, Lactococcus lactis; Sag, Streptococcus agalactiae.
Eco*, live E. coli-treatment.
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the blood stream a pathogen must withstand immune clearance by blood leukocytes. Because the
cpsY mutant was unable to disseminate to the brain, the requirement of CpsY for S. iniae survival in
whole blood was investigated. Both WT S. iniae and the cpsY mutant were incubated in human
whole blood for 3 hr and serially diluted onto THY agar plates to determine bacterial survival. WT S.
iniae displayed an ability to replicate in whole blood, reaching levels approximately 2 logs over the
inoculum (p < 0.05), while the cpsY mutant was almost completely killed under the same conditions
(p < 0.05) (Fig. 16). To determine if this difference in bacterial survival was due to phagocytic killing
by blood leukocytes, whole blood was pretreated for 30 min with cytochalasin D (CD), an inhibitor of
actin polymerization, to block phagocytosis. The addition of CD completely rescued the cpsY mutant
to WT levels (Fig. 16).

These results suggest that leukocyte phagocytic killing is the primary

bactericidal force against the cpsY mutant, and indicate a function for CpsY in the regulation of
factors required for protection of S. iniae from phagocytic clearance.
CpsY protects S. iniae from neutrophil intracellular killing.

To confirm that blood

leukocytes were responsible for the extensive killing of the cpsY mutant in whole blood, S. iniae WT
and the cpsY mutant were incubated 3 hr in either 50% human serum alone or with the addition of
primary peripheral blood neutrophils. Significant growth was observed for both WT and the cpsY
mutant in 50% human serum alone (p < 0.0001) (Fig. 17). Addition of neutrophils resulted in a
reduction of WT compared to serum alone (p = 0.0005) (Fig. 17), which was still significant growth
over the inoculum (p < 0.0001). In contrast, the cpsY mutant was highly attenuated with the addition
of neutrophils (p = 0.0001 compared to serum alone) (Fig. 17). Pretreatment of the neutrophils with
CD rescued both WT and the cpsY mutant back to the levels observed in serum alone (Fig. 17),
confirming the phenotype found in the whole blood.
HEMA-stained cytospin slide preparations of infected neutrophils (in 50% human serum)
revealed intracellular localization of both WT and the cpsY mutant within a vacuole (Fig. 18).
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Figure 16. S. iniae survival in human whole blood. Mid-log phase cultures of S. iniae WT (grey bars)
or cpsY (white bars) were diluted into 1 ml heparinized human whole blood, and incubated at 37 oC
with gentle rotation. Samples were serially diluted and plated on THY for enumeration of bacterial
CFU. For certain conditions blood was pretreated for 30 min with 10 g ml-1 cytochalasin D (CD).
Error bars represent  standard error. *p < 0.05 compared to WT.
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Figure 17. S. iniae neutrophil infections. Mid-logarithmic cultures of S. iniae WT (grey bars) or
cpsY (white bars) were diluted 1 ml DMEM 50 % human serum. When necessary, human primary
neutrophils (N) were added to a final MOI of 0.001 (bacteria:neutrophil). If required, neutrophils were
pretreated with 10 g ml-1 cytochalasin D (CD) for 30 min. Samples were incubated at 37 oC with
gentle rotation, followed by serial dilution and plating on TP for enumeration of bacterial CFU. Error
bars represent  standard error. * p < 0.01, ** p = 0.0001 compared to WT.
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Figure 18. Images of S. iniae neutrophil infections. S. iniae WT or cpsY were mixed with
neutrophils suspended in 1 ml DMEM with 50 % serum alone, with cytochalasin D pretreatment (CD),
or with 50 % heat-inactivated serum (HIS). After 3 hrs 100 l of the sample was cytocentrifuged on to
glass slides and stained for visualization. A representative image for each condition is shown. Black
arrows depict bacteria. Cell nuclei are noted with a white asterisk.
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Pretreatment with CD completely inhibited phagocytosis, but the bacteria remained closely associated
to the neutrophil outer surface (Fig. 18). Similar observations were made when serum was heat
inactivated prior to infection (Fig. 18). Thus, cpsY is not involved in preventing phagocytic uptake, but
rather must function to protect S. iniae within the neutrophil phagosome.
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Discussion
Bacteria have a variety of mechanisms for maintaining the required supply of nutrients needed
for survival in nutrient-limited environments by either de-novo synthesis or nutrient scavenging from
the external environment. While many of these pathways are functionally conserved in both Grampositive and Gram-negative bacteria, others differ markedly even within the same genera.
Streptococcal species appear to use the same general pathway for managing intracellular methionine
supply, although portions of the pathway appear to be missing in some species (Table 1).
The current collection of information on the streptococcal CpsY regulon is focused on its role
in methionine metabolism and uptake (259, 268). De-novo biosynthesis of methionine begins with the
generation of homocysteine through transsulfuration (MetB, MetI, MetC), direct sulfhydrylation
(MetB, MetY) or S-adenosylmethionine (SAM) recycling (MetK, Pfs, LuxS) pathways (Fig 6).
Homocysteine is then converted to methionine by the cobalamin-independent methionine synthase
(MetE) and 5,10-methylenetetrahydrofolate reductase (MetF) (268). Portions of these pathways are
incomplete in S. iniae, S. agalactiae and S. pyogenes (Table 1) (248) and in these pathogens
incomplete de-novo biosynthesis is thought to be balanced by environmental methionine scavenging
through the conserved AtmBDE (MetQ1NP, also called Abc,YaeEC) ABC transport system (248).
A comprehensive understanding of how streptococci regulate their repertoire of methionine
metabolic genes is still emerging. In Gram negative organisms, the MetJ repressor along with the
SAM cofactor controls transcription of the de novo methionine biosynthesis genes and the atmBDE
locus when methionine levels are sufficient (169).

Repression is relieved under sulfur limiting

conditions when methionine biosynthesis is required (113). In addition, the CpsY ortholog MetR
utilizes homocysteine as a cofactor to compete with the MetJ:SAM complex and increases methionine
biosynthesis through transcriptional activation of metE and metF when methionine levels are
insufficient (47, 65, 183, 234, 290-291).
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MetR is thought to be the primary regulator of methionine biosynthesis and uptake pathways
for streptococcal species due to the absence of a MetJ ortholog (158). In S. mutans, MetR-dependent
activation of metE and atmBDE occurs under methionine-limitation but not excess (268). Expression
of metE and atmB can be triggered in the presence of excess methionine only if excess homocysteine is
also present in the medium, because homocysteine is the activating co-factor for MetR (268). In S.
agalactiae, MtaR was shown to activate metQ1 (atmB) in the presence of excess methionine, but had
no effect on metE expression (42). The effect on metQ1 or metE in the absence of methionine was not
investigated in that study. S. iniae does not carry the metE or metF genes, but does contain genes
encoding the AtmBDE transporter. We show here that a CpsY-dependent increase in atmB expression
occurs in the presence of excess methionine, but not homocysteine. Thus as observed in other species,
CpsY appears to increase cellular methionine pools through transcriptional activation of the AtmBDE
transport system; however, the environmental condition under which this occurs differs between
species. Those species which contain a complete de novo methionine biosynthesis pathway (i.e. S.
mutans) limit expression of atmB in the presence of excess methionine and respond to homocysteine,
whereas those with incomplete pathways (i.e. S. iniae) increase expression of the transporter and do
not respond to homocysteine. This difference is not due to alterations in the promoter structure
because a canonical Met box (TATAGTTTnAAACTATA) was found in the same proximal location to
atmB in all species. This may possibly be due to differences in CpsY itself or additional regulatory
elements that function either in cis or in trans to influence the regulation of this locus.
The physiological explanation for these observed differences in S. iniae has yet to be
determined, but may be due in part to the absence of both MetE and MetF for conversion of
homocysteine to methionine. This conversion is a key step in recycling of the primary methyl donor
SAM (307). An inability to convert homocysteine back to methionine due to the absence of MetEF
would necessitate methionine scavenging for generation of SAM. Thus S. iniae may have evolved
alternate regulatory mechanisms to compensate for the lack of MetEF. S. pyogenes, S. uberis and S.
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equi also do not have the metEF genes (158), but whether their respective CpsY orthologs function
similar to S. iniae is unknown.
A systemic pathogen must adapt to one or more environments in the host and, as has been
shown for many pathogens, these adaptations involve metabolic changes. The work presented here
demonstrates a specific role for CpsY during S. iniae systemic infection. In addition to control of
methionine transport through regulation of the atmB gene, CpsY is critical for adaptation and survival
in the intracellular environment of neutrophils in whole blood. The enhanced susceptibility of the
cpsY mutant to neutrophil-mediated killing correlates with the attenuation initially observed in our
zebrafish infection model (185).
While CpsY is absolutely required for S. iniae survival in neutrophils, it appears dispensable
for survival in macrophages. This is supported in vivo where localization of S. iniae within splenic
macrophages of infected zebrafish is independent of CpsY. Contradictory was the observation that
intracellular localization within zebrafish macrophage-like cells in the brain is dependent upon CpsY.
An explanation for this dichotomy in vivo may be that the ability to survive and replicate in the blood
stream is a precursor for the establishment of a CNS infection (43, 84, 240, 318). Thus, the inability of
the cpsY mutant to localize within brain macrophages could be due to limited bacteremia in vivo, and
not susceptibility to macrophage-mediated killing within the brain. If the cpsY mutant were rapidly
cleared in the blood stream by neutrophils, then a decrease in the bacterial load at distant sites would
be expected. This explanation correlates with previous reports where the cpsY mutant displayed a
unique inability to acutely disseminate to the brain 30 minutes post intramuscular infection, while
bacterial loads in the spleen were equal to WT (185). Neutrophils are the primary phagocytic cell
found in the blood stream, and are vital for protection from invading pathogens (175). The ability to
exploit the host inflammatory response and survive within neutrophils is an important virulence trait of
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several pathogens including Staphylococcus aureus (110), Streptococcus pyogenes (196),
Streptococcus suis (306) and Listeria monocytogenes (81).
Mutations in orthologs of CpsY have been shown to influence growth in vitro due to the
disruption of methionine supply described above. This defect could be rescued with the addition of
exogenous methionine for S. agalactiae (42, 259) and S. mutans (268), but as shown here, not for S.
iniae. In contrast, addition of 2% proteose peptone resulted in unrestricted exponential growth for the
cpsY mutant while growth of the WT strain was unaffected. The data suggest that in S. iniae, CpsY
functions to maintain proper growth in vitro in a way that differs from S. agalactiae or S. mutans. The
inability of the cpsY mutant to maintain proper growth in vitro does not appear to be the cause of its
virulence attenuation. The cpsY mutant was highly attenuated in whole blood, but was able to grow
to WT levels upon inhibition of neutrophil phagocytosis by the addition of CD. Thus the attenuation
observed in whole blood is not due to a growth defect, but specifically the inability to survive
neutrophil phagocytosis. The sensitivity to phagocytosis is specific to neutrophils because growth in
macrophages was unaltered. Overall the data suggest that CpsY provides a unique virulence function
that allows S. iniae to adapt for intracellular survival within neutrophils.

The growth disparity

observed for the cpsY mutant in vitro appears to reflect an early entry into stationary phase, which
could suggest a defect in cell wall biosynthesis, cell stress response pathways or autolysin regulation
rather than an auxotrophic phenotype (245).
CpsY orthologs have also been implicated in the regulation of genes unrelated to methionine
acquisition. S. agalactiae MtaR affects the expression of a cell surfaces protease (cspA) and fibrinogen
binding protein (fsbB) implicated in streptococcal pathogenesis, as well as numerous genes involved in
arginine transport and sugar metabolism (42). In Pseudomonas aeruginosa, MetR has significant
effects on swarming motility in semi-viscous media, and was shown to control several transcriptional
regulators, a Type III secretion system, as well as pyoveridine and pyochelin synthesis genes (312).
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Furthermore, MetR in Vibrio harveii was shown to act directly on the luxCDABE operon to repress
luminescence independent of the quorum sensing AI1 and AI2 signal levels (57).
The data presented here demonstrate that CpsY has a pleiotropic regulatory effect on S. iniae
pathogenesis that extends beyond the traditional methionine metabolic processes. Furthermore, CpsY
may have been co-opted to provide regulatory input on virulence gene expression based on the
nutritional status of the cell. Moreover, S. iniae provides a unique model to investigate the paradigm
of CpsY-dependent regulation during systemic streptococcal infection due to the absence of a
methionine-dependent growth deficiency.
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CHAPTER 3
CpsY-dependent protection from neutrophil-mediated killing involves modification
and stabilization of the Streptococcus iniae cell wall

Abstract
The ability of a pathogen to evade neutrophil phagocytic killing mechanisms is critically
important for dissemination and establishment of a systemic infection. Understanding how pathogens
overcome these innate defenses is important for the development of optimal therapeutic strategies for
invasive infections. CpsY is a conserved transcriptional regulator previously identified as an important
virulence determinant for systemic infection of Streptococcus iniae. While orthologs of CpsY have
been associated with the regulation of methionine metabolism and uptake pathways, CpsY additionally
functions in protection from neutrophil-mediated killing. S. iniae does not alter neutrophil phagosomal
maturation, but instead is able to adapt to the extreme bactericidal environment of a mature neutrophil
phagosome dependent upon CpsY. This CpsY-dependent adaptation appears to involve stabilization
of the cell wall through peptidoglycan O-acetylation and repression of cellular autolysins. In addition,
CpsY may influence these processes by responding to nutritional stress.. Furthermore S. iniae proves
to be a powerful model to investigate bacterial adaptations during systemic streptococcal infection.
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Introduction
The ability of a systemic pathogen to evade or manipulate the host innate immune response is a
key factor in determining the severity of a bacterial infection (289). Polymorphonuclear leukocytes
(neutrophils) are a primary bactericidal force against invading bacteria, and represent a formidable
obstacle for pathogens to overcome (33). This is especially reflected in the susceptibility of patients
with inherited neutrophil disorders to severe bacterial infections (191). Neutrophils are efficient at
eliminating invading pathogens through both intracellular (256) and extracellular killing mechanisms
(222). Engulfed pathogens suffer a barrage of bactericidal attacks from exposure to reactive oxygen
and nitrogen species (172, 256), antimicrobial peptides (104, 241), proteases (48, 250, 264)
peptidoglycan degrading enzymes (211), and metal deprivation (135, 154, 217).
Invasive pathogens have evolved several strategies for evasion of neutrophil killing
mechanisms. Pathogens attempt to avoid phagocytic uptake through prevention of opsonin deposition
(282) and production of a polysaccharide capsule (179).

Engulfed pathogens can either disrupt

phagosomal maturation, escape into the cytoplasm or adapt for survival within the mature phagosome
(289). Adaptive processes for phagosomal survival occur in part through chemical modification of
outer surface structures including lysinylation of lipid membranes (92, 162, 251), D-alanylation of wall
teichoic acids (55, 100) and O-acetylation of N-acetylmuramyl peptidoglycan residues (20-21, 68).
Streptococcus iniae is an invasive pathogen of aquatic species that causes severe bacteremia
and meningoencephalitis (4, 88-89). The rapid dissemination of S. iniae to systemic sites reflects its
ability to survive and replicate in the blood stream (43, 101, 185). CpsY is a conserved transcriptional
regulator previously identified as an important virulence determinant for systemic infection of S. iniae
(185), and mutants of cpsY are specifically susceptible to neutrophil-mediated killing in whole blood
(Fig. 16). CpsY is orthologous to the MetR transcriptional regulator associated with methionine
metabolism and uptake pathways in Gram negative and Gram positive microorganisms.

MetR

increases cellular methionine pools in Streptococcus mutans and Streptococcus agalactiae through
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transcriptional activation of both an ABC transport system and methionine synthase (MetE) (42, 268).
Mutants of metR in these species display a severe growth defect and require exogenous methionine for
optimal growth (42, 268). S. iniae does not contain an ortholog of metE, but CpsY does function as a
transcriptional activator of the methionine ABC transporter. In contrast to S. mutans and S. agalactiae,
however, the effect of CpsY on growth of S. iniae is independent of exogenous methionine. Rather, a
strain deleted for the cpsY gene (cpsY) displays aberrant growth patterns, with final cell densities at
stationary phase reaching levels either significantly greater or less than WT dependent upon media
conditions. Furthermore, growth of the cpsY mutant could not explain the severe susceptibility to
neutrophil-mediated killing in whole blood. Thus the CpsY regulon must allow S. iniae to specifically
adapt for intracellular survival in neutrophils by a previously undetermined mechanism.
This work elucidates the role of CpsY for S. iniae intracellular survival in neutrophils. S. iniae
does not appear to disrupt neutrophil phagosomal maturation, instead the CpsY regulon protects S.
iniae from the bactericidal components contained within a mature phagosome. This protection appears
to be mediated in part by modifications to the peptidoglycan cell wall and repression of streptococcal
autolysins. Furthermore, we discuss how CpsY-dependent regulation of methionine supply pathways
may influence these processes.
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Materials and Methods
Bacterial strains, media and culture conditions. The parent S. iniae strain 9117 and a cpsY
in-frame deletion mutant (cpsY) used in this study have been described previously (185). All plasmid
constructs were propagated using Escherichia coli TOP10 cells (Invitrogen) cultured in Luria-Bertani
(LB) medium. Streptococcal strains were cultured in Todd-Hewitt broth (BBL) supplemented with
0.2% yeast extract (BBL) (THY) (189). Antibiotics were added to the medium when required at the
following concentrations: Kanamycin 25 g ml-1 or chloramphenicol 750 g ml-1 for E. coli;
Kanamycin 500 g ml-1, chloramphenicol 3 g ml-1 or streptomycin 1 mg ml-1 for S. iniae. Bacteria
were routinely cultured overnight, diluted 1:50 in fresh medium, and grown to mid-exponential phase
(OD600 = 0.225) unless otherwise stated. Bacterial growth curves were performed in 96-well plates as
described in Chapter 2.
Construction

of

S.

iniae

overexpression

mutants.

The

primers

5’murA.PstI

(AAAACTGCAGGAGAAGAAGAATAAAGCCTATAGTG) and 3’ murA.ApaI (TTGGGCCCCTAA
AGGCCTTTATTTGTCTTTG) were used to amplify an 860 base pair (bp) fragment containing the
MurNAc-L-alanine amidase (murA) (sin.1445). The fragment was inserted into the PstI/ApaI sites of
the vector pLZ12-km (116) generating pLZ12-km-murA.

The promoter of the hyaluronic acid

synthesis operon in Streptococcus pyogenes (67) was PCR amplified using primers 5’ hasApro.BglII
(GGAAGATCTCAGATGAAGTTGTACTCCCTG) and 3’hasApro.BamH1 (CGCGGATCCGGCAC
AATTACACCTCTTC). This fragment was inserted into the BglI/BamH1 sites in pLZ12-km-murA to
generate the final construct pLZ12-hasApro.murA.
The vector pLZ12-km-hasApro.murA was cut with PstI and ApaI to remove murA generating
pLZ12-km-hasApro. The primers 5’oatA.PstI (TGCACTGCAGCTTTAAACAGGGGATTTATCAAA
AATG) and 3’oatA.ApaI (TGGGGGCCCGACCTTATTTGGCCTTATTTTTG) were used to PCR
amplify an 1815 bp fragment containing the peptidoglycan O-acetyltransferase (oatA) (Sin.29). This

66
fragment was inserted into the PstI/ApaI sites of pLZ12-km-hasApro to generate the final construct
pLZ12-km-hasApro.oatA.

Both pLZ12-km-hasApro.murA and pLZ12-km-hasApro.oatA were

transformed into S. iniae as previously described (201).
Whole blood and neutrophil infection assays. Primary neutrophils were isolated from human
whole blood, and infections were performed in either whole blood or neutrophil preparations as
described in Chapter 2. For competition assays, neutrophils were infected as before with minor
variations. Mid-exponential phase cultures were adjusted to 1 x 105 CFU ml-1 in PBS, from which
equal volumes were pooled and inoculated 1:50 (20 l volume) into 1 ml neutrophil preparations.
Samples were incubated at 37 oC for 3 hr with gentle rotation, followed by serial dilution and replica
plating on THY agar  1000 g ml-1 streptomycin for bacterial enumeration. The competitive index
(CI) was calculated by dividing the output ratio (mutant/wild type) by the input ratio (mutant/wild
type).
Confocal laser scanning fluorescence microscopy.

S. iniae neutrophil infections were

performed as above for 1 hr. One hundred microliters of the sample was loaded into a cytology funnel
(Thermo), centrifuged onto glass slides for 3 min at 700 rpm in a Cytospin 1 centrifuge (Shandon
Elliott) and fixed in 4% paraformaldehyde (Sigma) for 15 min at room temperature. Fixed cells were
washed 3 times in PBS and treated for 30 min with 100 l of permeabilization buffer (0.2% Tween 20
in PBS + 10% mutanolysin). Cells were washed in PBS and covered for 30 min in blocking buffer
(2% cold water fish gelatin (Sigma) in PBS). One hundred microliters of a polyclonal anti-S. iniae
antibody was added to the cells for 2 hr, followed by washing 3 times in PBS.

One hundred

microliters of a secondary Alexa Fluor® 488-conjugated goat anti-rabbit antibody (Molecular Probes)
was added to the cells for 30 min, and again washed 3 times with PBS. This procedure was repeated a
second time using a monoclonal antibody specific for human PMN secondary granule marker CD107A
(LAMP1) (Santa Cruz Biotechnology) and a secondary Alexa Fluor® TRITC-conjugated goat anti-
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mouse antibody (Molecular Probes), or using a primary goat antibody for staining of human PMN
azurophil (primary) granule marker CD63 (Santa Cruz Biotechnology) and a secondary rhodamineconjugated chicken anti-goat antibody (Santa Cruz Biotechnology). Prepared cells were mounted in
ProLong® Gold antifade reagent with DAPI (Molecular Probes). Co-localization was determined by
fluorescent microscopy using a Leica TCS SP5 Laser Scanning Confocal Microscope.
Antimicrobial sensitivity assays. Working concentrations of the following antimicrobials
were prepared in THY broth: colistin (500 g ml-1; Sigma), gramicidin (1.5 g ml-1; Sigma),
carbenicillin (6 g ml-1; Sigma), methicillin (16 g ml-1; Sigma), teicoplanin (0.07 g ml-1; Sigma),
bacitracin (5 g ml-1; Sigma), nisin (40 g ml-1; Sigma) and LL-37 (500 g ml-1; Anaspec). Three
hundred microliter stock solutions were added to the last column of a 96-well flat bottom plate, and
serially diluted 1:2 into 150 l of THY broth. For lysozyme treatments, wells were prepared with
increasing concentrations of chicken egg white lysozyme (Sigma, 40K units mg-1) from 2.5 mg ml-1 to
25 mg ml-1 in 150 l total volume THY broth. Mid-exponential phase bacterial cultures were washed
twice in PBS and normalized to 1 x 105 CFU ml-1. Ten microliters of this resuspension was added to
each well, and plates were incubated overnight at 37oC. OD600 readings were measured using a
VersaMax microplate reader (Molecular Diagnostics). The minimal inhibitory concentration (MIC)
was scored as the lowest antimicrobial concentration with no detectable growth. For assays using LL37 antimicrobial assays were performed as described above except PBS was used in place of THY
broth. Plates were incubated at 37oC for only 3 hr, followed by serial dilution and plating on THY
agar. Minimal bactericidal concentration (MBC) was scored as the lowest antimicrobial concentration
with no detectable growth.
Bacterial surface charge assay. Bacteria grown in THY medium were normalized to an
OD600 = 6.0. Cultures were washed 2 times in 20 mM morpholinepropane-sulfonic acid (MOPS)
buffer (pH 7.0) and resuspended in 1 ml of the same buffer. Ten microliters of 50 mg ml-1 cytochrome
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c (Sigma) was added, mixed well and incubated 15 min at room temperature.

Samples were

centrifuged 13,000 x g for 5 min, supernatants were collected and measured at OD530 to determine the
amount of cytochrome c remaining. Tubes containing no bacteria were used as an input control. The
percentage cytochrome c bound was calculated with the following formula: [1- (output OD530/input
OD530)] x 100.
RNA isolation and quantitative PCR. Ten milliliters of bacterial cultures were used to purify
total RNA as described in chapter 2. For synthesis of cDNA, 2 g of total RNA was combined in 20
l reaction volumes with 0.2 M reverse primer mix (4 M mixture of each of the reverse primers
listed below), 0.5 mM dNTP mix, 1X RT buffer, and 200 U of Maxima® Reverse Transcriptase
(Fermentas). Reactions were incubated at 60 oC for 30 min followed by 85 oC for 5 min. For qPCR
reactions, 1 l of cDNA was combined in 20 l total reaction volumes with 0.2 M forward and
reverse primers, and 1X Maxima® SYBR Green master mix (Fermentas) per manufacturer instructions.
Primer sequences are as follows: recA (sin.996) fwd 5’-CTCAGGTGCTGTTGATTTGG-3’, rev 5’TGCAGAGAGTTTACGCATGG-3’; murA (sin.1445) fwd 5’-CGTAGTCGTGTATTT-3’, rev 5’TTGGGTTGTATGGTGAAGCA-3’; oatA (sin.29) fwd 5’-CTTTTCGGCTTTGTTCTTGC-3’, rev 5’TCCGCAAAGTATGTCAGCAC-3’; dltA (sin.295) fwd 5’-CACCGGTATGGTAAGCAGGT-3’, rev
5’-AAACGGAGAGCAAGGTGAAA-3’; pgdA (sin.822) fwd 5’-GATGGTCCAAACCCTGTGAC-3’,
rev 5’-ACCCGCTTCCTTGACTTTTT-3’; tagO (sin.1228) fwd 5’-GGTTCCTATGCCAAGTGGTG3’, rev 5’-ATTGCCGCTCCAATAACAAC-3’. Reactions were performed in triplicate using a BioRad
iCycler with the following cycling conditions: 10 min at 95 oC, 40 cycles of 15 sec 95 oC and 1 min 60
o

C. Melting curves were performed after completion of each experiment. Relative fold change in gene

expression was calculated by 2-(CT) as described in chapter 2.
Isolation and purification of peptidoglycan. S. iniae strains subcultured in 1 L of THY at 37
o

C to early stationary phase were rapidly cooled on ice for 5 min, and harvested by centrifugation
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(9,000 x g, 4oC) for 10 min. The pellet was resuspended in 15 ml of cold water and transferred
dropwise into 50 ml of boiling 4% sodium dodecyl sulfate (SDS) (Sigma) for 30 min. The SDS
insoluble fraction was collected by centrifugation (9,000 x g, 25oC) for 10 min, and washed with 60 oC
water until the SDS was undetectable by methylene blue assay (120). The cell wall fraction was
resuspended in 1 ml of 100 mM Tris-HCl (pH 7.5), 20 mM MgSO4 containing 10 g ml-1 DNaseI
(Qiagen), 250 g ml-1 RNaseA (Qiagen) and incubated for 2 hr at 37 oC. Calcium chloride was
adjusted to a final concentration of 10 mM, and 100 g Trypsin was added to the mixture prior to
incubation overnight at 37 oC. The samples were boiled in 1% SDS for 5 min to denature trypsin, and
the samples were washed clean of SDS as before. The purified peptidoglycan was lyophilized and
stored for later analysis.
Analysis of muropepetide composition. Muropeptides were analyzed as previously described
with minor variations (174). Five milligrams of lyophilized cell wall preparations were resuspended in
500 l 0.1M Tris HCl (pH 7) and 20 l of mutanolysin (5K U ml-1; Sigma), and incubated at 37oC
overnight. Samples were boiled 5 min, and the insoluble fraction was separated by centrifugation at
13,000 x g for 2 min. The muropeptide-containing supernatants were lyophilized, and resuspended in
5 l of a 0.2 M disodium 8-amino-1,3,6-naphthalenetrisulfonate (ANTS; Invitrogen) solution in 15%
Acetic Acid (Fisher) and 5 l of a 1 M sodium cyanoborohydride (Acros) solution in DMSO. The
samples were incubated overnight at 37 oC, dried by centrifugal vacuum and resuspended in 200 l
loading buffer (62.5 mM Tris HCl pH 6.8, 20% glycerol). One micromole of carbohydrate standards
of glucose (Sigma), maltose (Fisher), maltotriose (Acros), maltotetraose (MP Biomedicals),
maltopentaose (Sigma) and maltohexaose (MP Biomedicals) were also ANTS-labeled and resuspended
in 1 ml loading buffer. Labeled standards were combined to a final mixture of 1 nmol l-1 each.
Fluorophore-assisted carbohydrate electrophoresis (FACE) was performed in a Hoefer S600 gel
apparatus. The 0.5 mm-thick acrylamide gels (18 cm x 16 cm) were composed of a stacking (8%
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acrylamide, 0.2% bisacrylamide, 0.3 M Tris buffer pH 8.9) and running (32% polyacrylamide, 2.4%
bisacrylamide, 0.3 M Tris buffer pH 8.9) gel component. Fifteen microliters of prepared samples were
separated by electrophoresis at 4 oC for 2.5 hr, 35 mA in running buffer (0.192 M glycine, 25 mM Tris
pH 8.9). The muropeptide bands were visualized by UV exposure (310 nM) and photographed using
Cannon Powershot A650IS camera. Gels were analyzed for relative band intensity using Gel-Pro®
Analyzer software (MediaCybernetics).
Determination of peptidoglycan acetylation. For quantification of peptidoglycan acetylation
30 mg of lyophilized cell wall preparations were resuspended in 1.5 ml 80 mM sodium hydroxide, and
incubated at 37oC for 3 hr with shaking. The samples were ultracentrifuged (100,000 x g, 25oC) for 30
min to separate the insoluble wall fraction. The amount of released sodium acetate in the supernatant
was assayed with the acetic acid (AK) kit (Megazyme) using a VersaMax microplate reader
(Molecular Diagnostics). Standard curves were prepared from serial dilutions of sodium acetate
(Sigma) for quantification.
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Results
CpsY does not influence neutrophil phagosomal maturation. Because CpsY is critical for
intracellular survival in neutrophils, we sought to determine the mechanism behind this protective
function. S. pyogenes has been shown to escape neutrophil phagocytic killing by inhibiting fusion of
azurophilic granules with the maturing phagosome (269). To test whether CpsY functions to disrupt
neutrophil phagosomal maturation in a similar manner, infected neutrophils were fixed and dual
immunostained with antibodies against S. iniae, and either the secondary granule marker CD107A or
azurophilic granule marker CD63. Laser confocal fluorescent microscopy images revealed that both
WT and the cpsY mutant colocalize with secondary (Fig. 19A) and azurophilic granule markers (Fig.
19B), implying containment within a mature phagosome. The data suggest that S. iniae does not
manipulate phagosomal maturation in neutrophils as observed for S. pyogenes. This also indicates that
the protective function imparted by CpsY must occur within a mature neutrophil phagosome.
Though phagosomal maturation appears unaltered, CpsY may serve a protective role by
regulating factors that in some way disrupt the microenvironment within a mature phagosome. To
address this possible scenario, a 1:1 co-infection of neutrophils with WT S. iniae and the cpsY mutant
was performed to determine if the CpsY protein produced in the WT strain could rescue the mutant
strain when inhabiting the same phagosome. Co-infection of neutrophils had no effect on the cpsY
mutant, resulting in significant killing compared to WT (p < 0.01) and an extremely low competitive
index of 0.06 (Fig 20). Furthermore, when neutrophil phagocytosis was inhibited by pretreatment with
cytochalasin D (CD) or heat-inactivation of serum (HIS), growth of the cpsY mutant was restored to
the levels observed in serum alone (Fig 20). Therefore, these results indicate that CpsY does not
function to manipulate phagosomal maturation of neutrophils, but rather must regulate factors that
provide direct protection to S. iniae from neutrophil killing mechanisms within a mature phagosome.

72
S. iniae

CD107A
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Figure 19. S. iniae colocalization with neutrophil granule markers CD107A and CD63. Infected
Neutrophils were analyzed by confocal laser scanning fluorescence microscopy for localization of S.
iniae WT or cpsY (green) in relation to the human neutrophil secondary granule marker CD107A
(red) (A), or human neutrophil azurophil (primary) granule marker CD63 (red) (B). Shown is a
maximum projection of a sequential scan
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Figure 20. Neutrophil competition assay. Mid-logarithmic cultures of S. iniae WT (grey bars) and
cpsY (white bars) were inoculated at a 1:1 ratio into 1 ml DMEM with 50% human serum (Ser) or 50
% heat-inactivated serum (HIS). Human neutrophils (N) were added at a ratio of 1000:1 (N:bacteria).
If specified, neutrophils were pretreated with 10 g ml-1 cytochalasin D (CD) for 30 min to inhibit
phagocytosis. Samples were incubated at 37 oC for 3 hr with gentle rotation, followed by serial
dilution and replica plating on TP plates  1000 g ml-1 streptomycin for enumeration of bacterial
CFU. The competitive index (CI) was determined as described in materials and methods. Error bars
represent  standard error. * p < 0.001.
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The cpsY mutant has increased lysozyme sensitivity. Many of the bactericidal compounds
contained within a mature neutrophil phagosome target components of the bacterial cell wall. The
susceptibility of the cpsY mutant to neutrophil-mediated killing could imply that CpsY regulates
factors involved in cell wall physiology. This could manifest as a decreased resistance to cell walltargeting antibiotics or antimicrobial peptides. No differences in the minimal inhibitory concentration
(MIC) were observed for the antibiotics colistin, gramicidin, carbenecillin, methicillin, teicoplanin,
bacitracin, or the antimicrobial peptides nisin and LL-37 (Table 3). However, the cpsY mutant was
significantly more sensitive to lysozyme with a 50% decrease in the MIC compared to WT (Table 3).
The increased sensitivity of the cpsY mutant specifically to lysozyme suggests possible chemical
alterations in the cell wall (21). In support of this, the cpsY mutant displayed an altered surface
charge compared to the WT strain as determined by cytochrome C binding (Fig. 21). Taken together,
the data provide evidence for CpsY in the regulation of factors involved in modification of the cell
wall.
Deletion of cpsY reduces peptidoglycan acetylation. Lysozyme is an important component
of epithelial secretions and phagocytic cells (34, 63, 66), and thus an obstacle necessary for pathogenic
species to overcome. Lysozyme cleaves the -(1,4)-glycosidic bonds between the N-acetylmuramyl
(MurNAc) and N-acetylglucosamyl (GlcNAc) residues of peptidoglycan (PG).

Chemical

modifications of PG that increase lysozyme resistance include both the addition of O-linked acetyl
groups to the MurNAc residues by the OatA acetyltransferase (20), or removal of N-linked acetyl
groups of the GlcNAc residues by the PgdA deacetylase (299). Furthermore, the addition of wall
teichoic acids and their D-alanylation have been shown to affect susceptibility to many of the
antimicrobial peptides contained within neutrophil granules (235). To determine if CpsY influences
the expression of genes involved in these processes, we performed quantitative PCR (qPCR) on both
mid-logarithmic and stationary phase cultures of WT S. iniae and the cpsY mutant. Expression of a

75

WT
250

250

Colistin

0.0059

0.0059

Gramicidin

0.375

0.375

Carbenecilin

0.5

0.5

Methecillin

0.035

0.035

Teichoplanin

2.5

2.5

Bacitracin

5

5

Nisin

31.25

31.25

LL-37a

300000c

650000

Lysozymec
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Figure 21. Measurement of bacterial cell surface charge. S. iniae WT or cpsY were normalized to an
OD600 = 6.0, washed twice and resuspended in 20 mM MOPS buffer with 0.5 mg ml-1 cytochrome c
for 5 min. Samples were centrifuged and the OD540 of the supernatant was measured. The data
represent percentage bound compared to input control. Error bars represent  standard error. * p <
0.01
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putative PG O-acetyltransferase (oatA) was decreased > 2-fold in the cpsY mutant relative to WT
(Table 4). No change in expression was observed for genes involved in teichoic acid biosynthesis
(tagO), D-alanylation of teichoic acids (dltA) or PG N-deacetylation (pgdA).
To determine whether the decreased expression of oatA in the cpsY mutant was accompanied
with an actual decrease in PG acetylation, purified PG preparations were treated briefly with 80 mM
NaOH to release all O-linked acetyl groups (21). Quantification of released acetyl groups revealed >
20% decrease in the acetylation of PG from the cpsY mutant (Table 5).

Thus the increased

susceptibility of the cpsY mutant to lysozyme and intracellular killing by neutrophils may be due to
an inability to properly acetylate the cell wall.
The cpsY mutant contains altered muropeptide profiles. The CpsY ortholog MtaR of S.
agalactiae was previously shown to affect the expression of a diverse gene set (42). In an attempt to
gain further insight into the S. iniae CpsY regulon, the microarray data obtained from that study was
examined for differential expression of genes with probable effects on cell wall physiology. Relative
expression of a gene encoding a putative N-acetylmuramoyl-L-alanine amidase (SAN_0845) was
found to be increased over 2-fold compared to WT. Analysis of the S. iniae ortholog (murA) by qPCR
revealed the same 2-fold increased expression for the cpsY mutant relative to WT (Table 4). A
mutant strain was accordingly designed to mimic the cpsY mutant by expressing MurA under the
transcriptional control of a strong promoter within a WT background (10A63) in order to investigate
whether overexpression of MurA was responsible for the observed phenotypes associated with the
cpsY mutant.
N-acetylmuramoyl-L-alanine amidases (EC 3.5.1.28) breakdown PG muropeptides (single
disaccharide of GlcNAc and MurNAc with a peptide component) by hydrolyzing the bond between the
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Table 4. S. iniae qPCR results
Gene Function
murA MurNAc-L-alanine amidase

Pathway
Peptidoglycan recycling

oatA

Putative O-acetyltransferase

Peptidoglycan acetylation

dltA

D-alanine-poly(phosphoribitol) ligase

Teichoic Acid D-alanylization

pgdA

Peptidoglycan GlcNAc deacetylase

Peptidoglycan deacetylation

tagO

UDP-GlcNAc 1-P transferase

Teichoic Acid biosynthesis

a
b

Phasea
ML
ST
ML
ST
ML
ST
ML
ST
ML
ST

Growth phase: mid-logarithmic (ML); stationary (ST).
Relative fold change (N) gene expression for cpsY compared to WT (CT method).

FCNb
2.41  0.13
2.04  0.01
0.43  0.07
0.39  0.05
1.09  0.12
1.09  0.12
1.09  0.15
1.37  0.70
1.17  0.18
0.95  0.09
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Table 5. Peptidoglycan acetylation
Strain NaOAc concentration (pmol mg-1) a
WT
300.58  23.08
cpsY 238.32  10.16
a
pmol of released sodium acetate per mg of
purified peptidoglycan
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muramoyl residue of the glycan backbone and the L-amino acid residue of the peptide side chain, a
process required for cell division and PG recycling (245). An overproduction of these amidases could
result in disruption of the muropeptide unit, resulting in an unstable cell wall and an increased
susceptibility to neutrophil bactericidal killing mechanisms. To determine if overexpression of murA
altered the muropeptide composition of the cpsY mutant, muropeptides were prepared by mutanolysin
treatment of purified PG from WT S. iniae, the cpsY mutant and strain 10A63. These samples were
then analyzed by fluorophore-assisted carbohydrate electrophoresis (FACE) (314), which allows for
the differentiation of muropeptides based on their electrophoretic mobility profile. FACE analysis
revealed that the relative concentration of soluble oligomeric muropeptide structures (crosslinked
muropeptides) in the cpsY mutant was approximately half that of the WT strain (Table 6; M1-M5).
This was accompanied by an increase in monomeric muropeptides (individual disaccharides of
GlcNAc and MurNAc  peptides) (Table 6; M6-M7) and free MurNAc (M9) for the cpsY mutant.
The 10A63 strain displayed some similarities to that of the cpsY mutant; however, the other
differences were observed which differed from WT and the cpsY mutant. These results demonstrate
that the overexpression of murA observed in the cpsY mutant may significantly alter the PG
muropeptide profile; however, this is likely an additive effect in combination with other processes (i.e.
decreased acetylation) because overexpression of murA alone (10A63) is not enough to mimic the
muropeptide profile of the cpsY mutant.

This alteration in the cpsY mutant could suggest a

weakness in the stability of the cell wall, which could increase susceptibility of the cpsY mutant to
neutrophil killing mechanisms.
Individual complementation of the cpsY mutant does not rescue growth in vitro.
Deletion of cpsY was previously shown to affect S. iniae growth patterns such that the cpsY mutant
cultured in THY medium displayed a significant decrease in cell density upon entry into stationary
phase (Fig. 5). In contrast, supplementing THY medium with 2% proteose peptone allowed the cpsY
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Table 6. Muropeptide percent compositiona
Muropeptide Compoundb
WT
M1
Multimeric MurNAc-peptides 6.61  1.28
M2
3.29  0.42
M3
3.94  0.37
M4
15.47  3.62
M5
7.47  0.98
M6
5.76  2.78
M7
MurNAc-peptide
39.71  1.24
M8
GlcNAc
2.47  0.68
M9
MurNAc
15.29  3.19
a
Determined by FACE analysis
b
Muropeptide compound based on electrophoresis profile
standards (314).

cpsY
3.22  0.99
2.53  1.11
1.64  0.69
6.97  2.75
3.92  1.35
7.15  5.98
47.66  3.17
2.31  1.27
24.59 2.61

10A63
4.37  1.05
3.14  0.54
3.94  0.81
12.99  1.51
6.52  1.26
0.30  0.12
47.70  1.98
5.11  1.29
15.92  1.75

relative to known carbohydrate
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mutant to reach a final cell density significantly greater than WT (Fig. 5).

As shown here,

complementation of the cpsY mutant by expressing CpsY in trans (6A19) had a negligible effect on
growth (Fig. 22). The inability for CpsY complementation suggests that normal CpsY-dependent
regulation of effectors involved in growth is tightly controlled.
To determine whether a deficiency in OatA expression was the causative factor for aberrant
growth of the cpsY mutant, strains were designed to circumvent the normal CpsY-dependent
regulation by expressing OatA under transcriptional control of a strong promoter in the cpsY mutant
(11A26) as well as a WT control (11A25). S. iniae WT, the cpsY mutant, and strains 11A25, 11A26
and 10A63 were then cultured in THY or THY supplemented with 2% proteose peptone (TP) and
growth was monitored by measuring OD600 every 30 min. Overexpressing OatA (11A26) did not
rescue growth of the cpsY strain (Fig. 22). Rather, both 11A25 and 11A26 appeared to delay the start
of exponential growth, and showed a significant decrease in cell density by stationary phase relative to
their parent background (Fig. 22). Over expression of the murA gene in 10A63 resulted in no
deviation from WT growth (Fig. 22). The data suggest that the aberrant growth of the cpsY mutant is
a complex phenotype, which cannot be rescued or mimicked by individual complementation of CpsYregulated genes.
Complementation of the cpsY mutant does not prevent killing in whole blood. We sought
to determine whether the altered expression of OatA or MurA in the cpsY mutant was directly
responsible for the susceptibility to neutrophil-mediated killing in whole blood. S. iniae WT, the
cpsY mutant, and strains 6A19, 10A63, 11A25 and 11A26 were incubated in whole blood for 3 hr at
37 oC and plated to determine bacterial survival.

S. iniae WT and strains 11A25 and 10A63

constructed in a WT background were able survive in whole blood, whereas the cpsY mutant and
strains 6A19 and 11A26 constructed in a cpsY background were completely killed (Fig. 23).
Pretreatment with CD rescued growth for all strains indicating that the observed attenuation was due to
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Figure 22. Bacterial growth curves. Overnight cultures were diluted 1:50 into 96-well plates
containing 200 l of THY (A) or TP (B). Plates were incubated at 37 oC in 5% CO2, and OD600
measurements were recorded over 6.5 hr. Error bars represent  standard error. *p < 0.05 for all
cpsY background strains (cpsY, 11A26, 6A19) compared to WT.
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Figure 23. S. iniae survival in human whole blood. Mid-logarithmic phase cultures were diluted into
1 ml heparinized human whole blood, and incubated at 37 oC with gentle rotation. Samples were
serially diluted and plated on THY for enumeration of bacterial CFU. For certain conditions blood
was pretreated for 30 min with 10 g ml-1 CD to inhibit neutrophil phagocytosis. Error bars represent
 standard error. *p < 0.05.
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phagocytosis by neutrophils as previously described. To note, growth of 11A25 and 11A26 was
significantly less than the respective parent strains (p < 0.01), which correlates with the same growth
restriction for both strains observed in THY medium (Fig. 22). Overall the data indicate that the
protective effect of CpsY from neutrophil-mediated killing is through the tight regulation of multiple
factors.
Analysis of CpsY-regulated promoters. Previous work has shown that certain genes under
transcriptional control by Streptococcal orthologs of CpsY contain a highly conserved regulatory
element termed Met box within their promoter region (158, 268). The presence of a Met box in the
promoter region of a CpsY-regulated methionine ABC transport system (AtmBDE) suggests that this
same element facilitates CpsY-dependent regulation in S. iniae as well (Fig. 7).

We sought to

determine if transcriptional regulation of oatA or murA by CpsY could be through this conserved
element. The gene encoding OatA is predicted to be the 3rd gene of an operon (Fig 24A). Whether
murA is part of an operon in unknown, but the predicted promoter is immediately upstream of murA
(Fig. 24A). Analysis of the predicted promoter regions revealed the presence of a Met box within the
murA promoter, but not the oatA operon promoter (Fig. 24B). Additionally, although the promoters of
both murA and atmB contain the canonical Met box, a major structural difference exists for those
regions. Twenty-two nucleotides separate the Met box and -35 site in the atmB promoter, whereas
those elements are separated by 96 nucleotides in the murA promoter (Fig. 24B). This difference may
explain why CpsY transcriptionally activates expression of atmB (Table 2) while repressing murA
(Table 4). The absence of a Met box for oatA suggests the effect of CpsY on the expression of oatA
may be indirect or occur in combination with additional factors.
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Figure 24. Promoter alignment for CpsY-regulated genes. (A) Genetic locations of AtmBDE
(Sin.1702-1699), MurA (Sin.1445) and OatA (Sin.29). (B) Predicted promote sequences obtained
from GenBank were aligned and plotted using ClustalX. The predicted -10 and -35 sites are
underlined, translational start codon is italicized, and predicted Met boxes are shaded.
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Discussion
Neutrophil phagocytosis of an opsonized pathogen is an intricate process whereby sequential
maturation of the phagosome generates a highly bactericidal microenvironment (172, 256). Pathogens
within the nascent phagosome are exposed to a burst of reactive oxygen species upon assembly of the
NADPH oxidase. Phagosomal maturation ensues with successive fusion of pre-formed gelatinase,
specific, and azurophilic granules that contain an arsenal of bactericidal compounds (256).
Engulfed microbes endure a multi-targeted attack within a mature phagosome. Transporters
such as the natural resistance-associated macrophage protein 1 (Nramp1) (135) and chelating agents
like neutrophil gelatinase-associated lipocalin (NGAL) (154) and lactoferrin (217) deprive
microorganisms of vital metals such as iron, manganese, and zinc. Bacterial lipid membranes are the
target of cytotoxic pore-forming antimicrobial peptides such as cathelicidins (241) and defensins (104)
with bactericidal activity against both Gram negative and Gram positive bacteria.

Furthermore,

myloperoxidase can react with hydrogen peroxide to generate hypochlorous acid (HOCl), tyrosine
radicals and reactive nitrogen intermediates, all of which can attack the surface membranes of
microorganisms (155). Engulfed pathogens are also exposed to serprocidins (serine proteases with
microbicidal activity) like proteinase-3, cathepsin G and elastase (48, 250, 264), as well as lysozyme,
which has both muramidase-dependent and independent antimicrobial activity (211).
Bacterial pathogens employ 3 characterized strategies for intracellular survival in neutrophils:
inhibition of phagosomal maturation, survival within a mature phagosome, or escape into the
cytoplasm (289).

S. pyogenes evades intracellular neutrophil killing by inhibiting phagosomal

maturation through an uncharacterized mechanism involving M protein (269).

In contrast, we

demonstrate that phagosomal maturation is unaltered in S. iniae-infected neutrophils, as determined by
co-localization with both azurophilic and specific granules. Thus the high degree of attenuation
observed for the cpsY mutant upon phagocytosis must be due to the disregulation of specific factors
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required for survival within a mature phagosome. These CpsY-regulated factors must be acting
directly on the bacteria rather than manipulating the phagosomal microenvironment due to the inability
of WT S. iniae to rescue the cpsY mutant during co-infection of neutrophils.
Protection from the bactericidal components encountered within a mature neutrophil
phagosome begins in part with sensory input from a variety of two-component systems (TCS),
resulting in the activation of cell stress response and wall modification programs (160, 173, 233, 240,
279, 294). These systems can activate enzymes that allow the bacteria to decorate both the cell
membrane and cell wall with various chemical modifications. For example, lipid lysinylation of the
cellular membrane by MprF (92, 162, 225, 283) (251) and D-alanylation of wall teichoic acids by the
DltABC locus (55, 100, 157, 159, 161, 235) provide protection from cationic antimicrobial peptides.
Resistance to lysozyme occurs through PG acetylation of MurNAc residues by the OatA Oacetyltransferase found in Gram positive organisms (20-21, 68, 126, 294) or the PatA/PatB system in
Gram negative organisms (206). Additionally the PgdA N-deacetylase mediates lysozyme resistance
through deacetylation of PG GluNAc residues (32, 199, 298-299, 301). The significant increase in
lysozyme sensitivity of the cpsY mutant without a concomitant change in sensitivity to -lactam
antibiotics or antimicrobial peptides tested suggests possible specific chemical modifications to PG
such as O-acetylation or N-deacetylation. The decrease in oatA expression for the cpsY mutant with a
concomitant reduction in total PG acetylation suggest that susceptibility to neutrophil-mediated killing
may be due to the inability to properly acetylate the cell wall.
The OatA O-acetyltransferase was originally identified in pathogenic staphylococci (20-21),
and homologs have been described for Streptococcus pneumoniae (68), Enterococcus faecalis (121)
and Lactococcus lactis (294). OatA is a membrane spanning protein thought to utilize cytoplasmic
acetyl-CoA as a donor for the translocation of acetate to the C6 hydroxyl group of MurNAc residues in
the murein sacculus (166). In L. lactis the CesSR TCS responds to lysozyme-induced cell envelope
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stress by activation of OatA through the intermediate SpxB regulator (294). CesSR homologs have
also been shown to respond to cell envelope stress for S. pneumoniae (91, 114), S. mutans (279), S.
aureus (164), B. licheniformis (302) and B. subtilis (139). S. iniae also contains a CesSR homolog;
however, its functionality in cell envelope stress response is unknown. Whether the reduced PG
acetylation observed for the cpsY mutant is influenced by the CesSR stress response pathway is yet to
be determined. The observed reduction in PG acetylation of the cpsY mutant could alternatively
represent an inability to accumulate actetylated PG through exponential growth into stationary phase
rather than an effect of stress response (166, 226). The absence of a Met box in the predicted oatA
promoter suggests an indirect effect by CpsY. Attempts to complement the cpsY mutant through
overexpression of OatA were unsuccessful, resulting in slight growth retardation and continued
susceptibility to neutrophil-mediated killing in whole blood. Similar observations have been made for
PG hyperacetylation in L. lactis (294) and Lactobacillus planeterum (24), suggesting that tight
regulation of the O-acetyltransferase is necessary for optimal growth.
The observed decrease in PG acetylation for the cpsY mutant could result in an increased
sensitivity to the cell’s own autolysins (29, 224). These PG hydrolases encompass several distinct
enzymes including the N-acetylmuramidases, N-acetylglucosaminidases, N-acetylmuramyl–L-alanine
amidases and lytic transglycosylases, all of which perform specific enzymatic functions necessary for
cell wall growth, turnover and separation during cellular division (245). The strict spatial and temporal
control of these enzymes is critical for prevention of unregulated PG hydrolysis (286).

PG O-

acetylation can inhibit certain autolysins such as lytic transglycosylases (29, 224), whereas others such
as the N-acetylmuramyl-L-alanine amidases are unaffected (28, 226). As shown here, CpsY acts as a
transcriptional repressor of a putative N-acetylmuramoyl-L-alanine amidase (MurA), presumably
through interactions with the conserved Met box in the MurA promoter. N-acetylmuramoyl-L-alanine
amidases play an important role in separation during cell division (51, 106, 124, 166, 237), and can be
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potent autolysins when overexpressed (124-125).

The increased expression of murA along with

decreased PG acetylation could render the cpsY mutant susceptible to detrimental restructuring of the
murein sacculus, thereby increasing the sensitivity to many of the bactericidal factors contained within
a neutrophil phagosome.

FACE analysis revealed a reduction in the proportion of oligomeric

muropeptide structures (crosslinked soluble muropeptides) for the cpsY mutant with a concomitant
increase in single muropeptides and free MurNAc and GluNAc residues, indicative of an altered cell
wall. Overexpression of MurA alone in WT S. iniae (10A63) did not produce the same muropeptide
profile observed for the cpsY mutant, and resulted in little difference from WT for growth or
susceptibility to killing in whole blood. Thus simply overexpression of MurA, perhaps without an
accompanying decrease in PG acetylation, does not explain the susceptibility to neutrophil-mediated
killing observed for the cpsY mutant.
CpsY is orthologous to the MetR regulator of methionine metabolism and uptake pathways in
Gram positive and Gram negative bacteria. MetR was originally characterized for its regulation of
methionine supply through activation of both the cobalamin-independent methionine synthase
(MetE)/5,10-methylenetetrahydrofolate reductase (MetF) for conversion of homocysteine to
methionine, as well as a methionine ABC transport system (AtmBDE) (268). S. iniae does not possess
the genes encoding MetE or MetF, but CpsY does function as a transcriptional activator of AtmBDE.
MetR mutants of S. mutans and S. agalactiae display a growth defect in serum, which can be rescued
in the presence of exogenous methionine (42, 259, 268). In contrast, the serum growth defect of the S.
iniae cpsY mutant was shown to be independent of methionine. Rather, the cpsY mutant displayed
aberrant growth patterns in which the final cell density reached levels significantly greater or less than
WT dependent upon the culture medium. This suggests that the CpsY regulon may act on processes
involved in cell growth and division rather than simply methionine uptake and metabolism.
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Furthermore this likely involves multiple elements as attempts to individually complement CpsYregulated genes were unsuccessful in restoring WT growth.
In E. coli cellular growth and division was recently shown to be strongly influenced by the
supply of both S-adenosylmethionine (SAM) and an undefined single-carbon (C1) tetrahydrofolate
(THF) derivative (317). Zhang et al. observed that a mutant strain of E. coli lacking all L-serine
deaminases was unable to control cellular division resulting in long chains of cells with abnormal
bulging morphologies when cultured in medium containing 0.5% casamino acids (CAA) (317).
Supplementing the medium with exogenous SAM partially restored the mutant to the natural rodshaped morphology of WT E. coli; however, the cells were still unable to properly separate during
division resulting in extended chains of long narrow cells. Moreover, overexpression of the glycine
cleavage operon (GCV), which breaks down glycine for synthesis of 5,10-methyleneTHF, in the serine
deaminase mutant fully restored WT cell morphology when cultured in the CAA medium.
A supply of C1-THF derivatives such as 5,10-methyleneTHF is required for the synthesis of
methionine, which is then converted to SAM by the S-adenosylmethionine synthase (Fig. 1). Thus
mutations which disrupt either the supply of methionine or C1-THF derivatives ultimately limit the
production of SAM. Normally the both the GlyA serine hydroxymethyltransferase and GCV act to
increase cytoplasmic pools of 5,10-methyleneTHF through breakdown of serine and glycine
respectively. The buildup excess of cytoplasmic glycine caused by growth in a complex amino acid
mixture such as CAA can result in the inhibition GlyA. The resultant accumulation of serine can then
act to inhibit the GCV, which is then unable to breakdown glycine and the inhibition is exacerbated
(317). Normally cellular serine deaminases decrease cytoplasmic serine pools to a stable level so as to
limit this inhibitory cycle; however, in the E. coli serine deaminase mutant this inhibition could not be
relieved. Thus the mutant strain became starved for C1-metabolites due to the inability to generate
THF derivatives through the breakdown of serine and glycine. The ability of exogenous SAM to limit
the bulging cell morphology of the serine deaminase mutant indicates a possible role for SAM in cell
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wall physiology; however, the ability of GCV overexpression to fully restore WT cellular morphology
suggests that an additional process influenced by C1-THF derivatives is ultimately involved in cell
division. Thus proper cell growth and division appears to depend on the metabolic state of the cell,
and both C1-THF and SAM may be needed for activation of the cell division machinery (317).
Intriguingly, MetR is also a transcriptional activator of GlyA in E. coli (65).

A MetR-

dependent increase in GlyA production would increase the cytoplasmic pool of C1-THF derivatives.
Thus MetR functions to increase production of C1-THF derivatives through transcriptional activation
of GlyA, as well as activation of methionine synthesis and uptake pathways for generation of SAM,
both of which are required for proper cell division. Whether SAM and C1-THF derivatives are
required for cellular division in S. iniae is unknown. In addition, CpsY-dependent regulation of GlyA
expression has not been investigated; however, a canonical Met box exists among streptococcal species
in the predicted promoter region of a gene encoding a 5,10-methylenetetrahydrofolate dehydrogenase
(FolD) (Fig. 1) (158), suggesting that that CpsY does regulate C1–THF metabolic processes for
streptococcal species as well.

Whether disruption of these processes accounts for the growth

phenotypes and virulence attenuation of the cpsY mutant remains to be determined.
Methylation reactions involving SAM result in the production of intermediates such as Sadenosylhomocysteine (SAH) and S-ribosylhomocysteine (SRH), which are recycled back to
homocysteine by the methylthioadenosine nucleosidase (Pfs) and S-ribosylhomocysteinase (LuxS)
(Fig. 6). Mutations of LuxS result in the inability to properly recycle SAH and SRH, and the
concomitant buildup of SAH in a LuxS mutant can inhibit many SAM-dependent methyltransferases
(257). Recently it was observed that LuxS mediates protection of S. pneumoniae from autolysis by the
major LytA autolysin, an N-acetylmuramyl-L-alanine amidase (17), through an unknown mechanism
(249). Whether the LytA-dependent autolytic phenotype in the LuxS mutant was the result of a direct
disregulation of LytA or an SAH-mediated inhibition of cellular methyltransferases was not
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determined. This work does however provide evidence for a link between processes involving both
SAM and autolysis in streptococci.

Because CpsY influences both of these processes through

activation of methionine supply pathways which ultimately lead to synthesis of SAM, and direct
repression of an N-acetylmuramyl-L-alanine amidase, the observed growth phenotypes and virulence
attenuation of the cpsY mutant could be due to the inability to properly regulate autolysis.
Protection from LytA-dependent autolysis has also been linked to the CiaRH TCS (111, 205).
Furthermore, the simultaneous mutation of both ciaRH and luxS has an additive autolytic effect in S.
pneumoniae (249). Pneumococcal CiaRH directly influences transcription at 15 promoters, 5 of which
regulate production of small RNAs involved in the control of stationary-phase autolysis (115). CiaRH
has also been shown to play a role in S. agalactiae lysozyme resistance and protection from neutrophilmediated killing (240). Whether the CiaRH TCS of S. iniae also functions to protect the cell from
autolysis has yet to be determined. Furthermore it is unknown whether CpsY has a regulatory role in
the expression of CiaRH or vice versa. Ultimately it appears that the relationship between SAM and
control of cellular autolysis is extremely complex and multifaceted, but could have considerable
influence on cell wall physiology and virulence.
A delicate balance exists in which SAM and C1 derivatives influence both cellular autolysins
and division machinery. These processes are tightly controlled, and disregulation has considerable
implications on growth and virulence. CpsY could influence this balance by increasing AtmBDE and
GlyA production for the generation of SAM and C1 derivatives respectively, while at the same time
repressing the expression of cellular autolysins (i.e. MurA). The inability to complement the cpsY
mutation reflects this pleiotropic function. CpsY is a complex transcriptional regulator, and the high
degree of conservation is indicative of its critical importance for basic processes of all prokaryotic
microorganisms. Variations in the CpsY regulon, however, can manifest as a diversity of speciesspecific phenotypes, and likely represent environmental niche adaptations. Many different metabolic
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pathways converge on cell division and PG biosynthesis, and mutants in components of these
pathways often share similar virulence phenotypes.

For example, S. iniae mutants of

phosphoglucomutase (PgmA) (44) and S. mutans mutants of phosphoglucosamine mutase (GlmM)
(311) also display similar increases in lysozyme sensitivity, susceptibility to neutrophil-mediated
killing and virulence attenuation in vivo. The common attenuation observed upon mutations within
these converging pathways suggests that combinational therapies targeting these basic processes would
be a powerful treatment strategy.

95
CHAPTER 4
General Conclusions

Invasive streptococcal disease remains a global health concern that has been exacerbated by
difficulties in vaccine design and emerging unprotected strains. The use of alternative models to
investigate invasive streptococcal disease may provide a necessary understanding of the detailed
mechanisms behind streptococcal infections. We describe here the use of Streptococcus iniae as a
model organism to investigate the role of a conserved transcriptional regulator, CpsY, in invasive
disease. CpsY is orthologous to the ubiquitous MetR transcriptional regulator found in Gram negative
and Gram positive bacteria. A primary function of MetR is to increase transcription of the genes
endoding the cobalamin-independent (MetE) and cobalamin-dependent (MetH) methionine synthase
and 5,10-methyleneTHF reductase (MetF) for biosynthesis of methionine from homocysteine. In
Gram negative bacteria MetR also increases expression of the GlyA serine hydroxymethyltransferase
to increase synthesis of 5,10-methyleneTHF (60), the required methyl donor for the conversion of
homocysteine to methionine by MetE and MetH. In Gram positive bacteria, MetR regulation of GlyA
has never been shown, but MetR does have moderate transcriptional control of the genes encoding an
ABC methionine transport system, AtmBDE (MetQ1NP). Thus, a general function of MetR is to
increase cellular methionine pools through transcriptional activation of de-novo biosynthetic and
transport machinery.
In Gram negative bacteria, a second level of transcriptional control of methionine synthesis and
transport processes involves the MetJ:SAM repressor complex. When SAM levels are high, indicative
of a sufficient methionine pool, MetJ utilizes SAM as a cofactor to bind to the Gram negative Metbox
within the promoter regions of most genes involved in the synthesis of methionine as well as glyA
encoding a serine hydroxymethyltransferase.

When SAM levels drop, indicative of a shrinking

methionine pool, this repression is relieved, allowing the bacteria to quickly respond to decreasing
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SAM levels as a trigger to increase methionine biosynthesis before cellular methionine concentrations
drop to a critical level, which could effect translational processes. This also includes derepression of
the genes encoding the methionine transporter (AtmBDE) to import extracellular methionine, although
multiple transport systems are thought to have methionine transport capability (103, 143). There are
no known homologs of MetJ in Gram positive organisms.
In Streptococcus mutans, mutants of metR display a severe growth defect in a chemically
defined medium lacking methionine (268). The growth defect is due to the inability to properly
express the metEF genes for de-novo synthesis of methionine. This growth defect can be rescued to
WT levels with a sufficient supply of exogenous methionine. In S. mutans, MetR has substantially
greater transcriptional control over metEF than atmBDE (30-fold vs. 3 fold respectively) under
methionine limitation, or with sufficient methionine in the presence of excess homocysteine,
suggesting that a primary function of MetR is to regulate de novo synthesis of methionine rather than
environmental scavenging.

In Streptococcus agalactiae, mutants of mtaR (metR) also display a

significant growth defect in chemically defined medium in the absence of methionine, and as with S.
mutans growth is rescued when the medium is supplemented with methionine (259). Unlike S. mutans,
MtaR control of MetEF and AtmBDE expression has not been studied under methionine limitation. In
the presence of sufficient methionine, MtaR is a transcriptional activator of atmBDE but not metEF
(42). This transcriptional activation of atmBDE in the presence of methionine is opposite to the
expression profile observed in S. mutans (268) suggestive of altered MtaR regulatory function.
Though S. agalactiae contains MetEF for synthesis of methionine from homocysteine as well as the
genes for the recycling of SAM to homocysteine, it lacks genes required for the biosynthesis of
homocysteine from cysteine. Thus the altered transcriptional control observed for the genes encoding
the AtmBDE transporter may be reflective of this difference. Understanding MtaR regulation in S.
agalactiae under methionine limitation, especially of MetEF, would be of significant value.
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A small subset of streptococcal pathogens, including S. iniae and S. pyogenes, lack the genes
encoding MetEF, but do contain homologs of the AtmBDE transporter. Kovaleva and Gelfand have
proposed that for these auxotrophs methionine must be obtained through extracellular scavenging and
peptide recycling (158). As with S. mutans and S. agalactiae a significant growth defect was observed
in either serum or THY medium for the S. iniae cpsY mutant; however, this was unable to be rescued
with exogenous methionine. This growth defect was not the result of a significant difference in the
logarithmic growth rate but rather represented an early entry into stationary phase growth resulting in
decreased final cell density. Whereas the cpsY mutant displays a significant methionine-independent
growth defect in serum or THY medium, growth in C-medium was equivalent to WT ( methionine),
suggesting that the effect of CpsY in S. iniae is not solely to regulate methionine acquisition. If this
were the case one would expect a similar growth defect in C-medium as observed in THY. Moreover,
the ability to induce significant growth of the cpsY mutant in excess of WT by supplementing either
THY or C-medium with 2% proteose peptone suggests that the cpsY mutant is unable to properly
control logarithmic growth and entry into stationary phase dependent upon environmental conditions.
CpsY regulation of the genes encoding the AtmBDE methionine transporter was shown to
occur in the presence but not absence of methionine as observed for S. agalactiae. Moreover, the
addition of exogenous homocysteine has no significant effect on this regulation in contrast to S.
mutans. Additionally, when grown in THY medium supplemented with proteose peptone, CpsY
appears to act as a transcriptional repressor of atmBDE. CpsY orthologs have been shown to regulate
effector targets through the conserved Metbox. No observable differences were found in the genetic
location of a Metbox in the atmBDE promoter, which suggests that the drastic differences in
transcriptional regulation observed under varying environmental conditions is due to additional
regulation at that site.
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Thus, although MetR orthologous mutants of S. mutans and S. agalactiae share a methioninedependent growth defect in chemically defined medium, MetR regulation of atmBDE is inhibited in
the presence of methionine for S. mutans but activated for S. agalactiae and S. iniae. Moreover,
though CpsY of S. iniae shares similar transcriptional regulation of atmBDE as S. agalactiae, the
growth defect of the cpsY mutant cannot be rescued with exogenous methionine. Because S. iniae is
purely auxotrophic due to the absence of MetEF, it is likely that there are other mechanisms for
obtaining methionine as proposed for Gram negative bacteria and suggests that the growth effects
observed for the cpsY mutant are due to a disregulation of other factors. Moreover, the data highlight
major differences in the streptococcal methionine supply pathways, suggesting that greater variability
in methionine acquisition may exist than previously recognized.
Disregulation of growth as observed for the cpsY mutant in response to peptone
supplementation could indicate a function for CpsY in either the RelA-dependent stringent response or
the RelA-independent stress response pathways, which are responsible for coordinating cellular
division and entry into stationary phase growth in response to amino acid starvation. The RelAdependent stringent response pathway is a cellular stress response to amino acid starvation that has
widespread effects on growth and virulence (74). A decrease in cellular amino acids results in a shift
in the ratio of uncharged to charged tRNAs. RelA is associated with ribosomes and is activated by the
presence of uncharged tRNAs in the ribosomal A site. Activation of RelA triggers its own synthetase
activity for synthesis of guanosine 3’,5’-bispyrophosphate (ppGpp).

Levels of ppGpp are also

controlled by SpoT. SpoT has both a basal ppGpp hydrolase activity and inducible synthetase activity
dependent upon cellular starvation of carbon sources, fatty acids, phosphates, iron and energy
depletion. Together RelA/SpoT are responsible for any accumulation of ppGpp in the cell. The
synthesized ppGpp can bind to the -subunit of RNA polymerase to affect promoter specificity and
facilitates outcompetition of the RpoS sigma factor with the housekeeping 70. Activation of the

99
stringent response results in a decrease in rRNA biosynthesis, ribosomal proteins and DNA replication
with a concomitant increase in RpoS, stress proteins and amino acid biosynthesis machinery all of
which have major implication on bacterial growth and division and help coordinate entry into
stationary phase growth.
Where RelA-dependent responses allow the cell to shut down energy intensive metabolic
processes in response to nutrient starvation, RelA-independent systems also respond to nutrient
limitation to initiate several systems involved in nutrient acquisition (272).

The transcriptional

regulator CodY binds both branched chain amino acids (BCAA) and GTP as cofactors, and inhibits
expression of many genes associated with adaptive responses to poor growth conditions including
stationary phase adaptation, virulence and nutrient stress (266). CodY normally represses these genes
during exponential growth, and induces them when the cell encounters nutrient limitation as the
growth rate diminishes. As cellular amino acid concentrations diminish, RelA reduces GTP pools by
synthesizing ppGpp. The reduction of both GTP and BCAA results in derepression of CodY-regulated
genes.

CodY-regulated genes derepressed under amino acid starvation include the oligopeptide

permease (opp), intracellular peptidase (pepB), covRS, virulence associated fas operon, streptolysin S
operon, luxS and ropB which results in activation of the SpeB extracellular protease. Many of these
genes encode virulence factors which result in the destruction of host cells and tissues.

This

destruction most likely releases various peptides and nucleotides, which are then scavenged and
recycled by the cell for nutrients. CodY and RelA don’t regulate each other, and thus appear to
influence the expression of separate, but complimentary, nutrient stress response programs in response
to decreasing amino acid supplies (192).
The specifics as to how CpsY could function as part of RelA-dependent or independent
response pathways is unclear. Kang et al. (145) recently described an additional arm of the RelAindependent amino acid response pathway involving CvfA, a general RNase that regulates virulence
gene expression in response to nutrient stress and cellular growth phase. CvfA couples with the
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glycolytic enzyme enolase to direct degradation of transcripts associated with various aspects of cell
transport, metabolism and energy production, and increase the expression of virulence factors such as
SpeB, SLS and the mitogenic factor, an extracellular DNase. Previously, comparison of protein
extracts from S. iniae WT and the cpsY mutant revealed an increase in the level of enolase as
determined by mass spectrometry analysis (201). Though it is unknown if CpsY directly regulates
expression of enolase, the increased enolase levels in the cpsY mutant could have significant effects
on these types of stress response pathways. Additionally, the B. subtilis CvfA homolog, YmdA,
drastically affects transcript stability such that mutants of ymdA display over 2-fold increase in the half
life of cellular mRNA (64). Although not specifically measured, noticeably more total RNA was
routinely isolated from the cpsY mutant compared to WT S. iniae. This could also indicate an
influence on a similar pathway involving transcript stability.
A common theme gaining acceptance in the literature is that mutations which limit the ability
of streptococci to respond to nutritional stress result in a severe attenuation in vivo (148-149). The
association of CpsY and its orthologs with methionine biosynthesis and uptake pathways suggests that
this may also be true for the cpsY mutant. Mutation of cpsY had significant effects on S. iniae
virulence due to an increased susceptibility to neutrophil-mediated killing in whole blood. This
attenuation in whole blood may explain the significant decrease in CNS invasion previously described
for the cpsY mutant (185), because the inability for maintaining a significant level of bacteremia is
considered an important prerequisite for invasion through the vascular endothelial barriers of the brain
(43, 84, 240, 318). The susceptibility of the cpsY mutant to neutrophil-mediated killing likely reflects
an inability to properly modify the cell wall, which leads to an increased sensitivity to lysozyme and
other neutrophil microbicidal compounds. This increased lysozyme sensitivity may be due in part to
the inability to properly acetylate PG, as indicated by decreased expression of oatA and reduction in
acetylated PG.

The disruption of PG acetylation must be tightly controlled, however, since
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overexpression of oatA results in growth retardation. The specifics as to how CpsY influences these
properties are still unclear. The lack of a proper Metbox in the predicted oatA promoter region is
suggestive of an indirect effect by CpsY, but the possibility of weak interactions at the promoter
cannot be discounted.
CpsY also appears to directly limit the expression of a major autolysin. Limiting expression of
a cell wall autolysin could promote stability of the cell especially in times of environmental stress such
as that found within mature neutrophil phagosomes. Attempts to replicate phenotypes of the cpsY
mutant through overexpression of the autolysin in WT S. iniae were unsuccessful indicating that any
detrimental effect of overexpressing the autolysin exists only when coupled with other alterations
occurring in the cpsY mutant. CpsY-coordinated actions which limit the expression of cell wall
recycling machinery (i.e. MurA) and increase the ability to protect against wall degrading
antimicrobial factors (i.e. OatA) could represent an important piece of a stress response pathway for
survival in vivo. The inability to complement the cpsY mutant suggests that the regulation imparted
by CpsY is multifaceted and represents tightly controlled adaptive changes.
As discussed in chapter 3, a delicate balance exists in terms of how pathways integrated with
metabolites such as SAM or C1-THF derivatives influence both cellular autolysins (249) and division
machinery (317). However, the ineffectiveness of exogenous methionine in rescuing the cpsY mutant
suggests that the high degree of attenuation is not due strictly to disruption in the regulation of
methionine supply pathways contributing to cytoplasmic pools of SAM.

The effect of adding

exogenous SAM to cultures of the cpsY mutant was never tested and would be of interest; however
no CpsY-dependent effect on the expression or activity of MetK has ever been observed, and in the
experiments where exogenous methionine was added it is likely that the methionine would be
converted to SAM if necessary for the cell.
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The complexity observed with mutation of CpsY in S. iniae suggests that this transcriptional
regulator maintains tight control over multiple processes. This would make CpsY a good mark for
targeted antimicrobial therapies, for example with small molecule inhibitors. Furthermore, utilizing S.
iniae to study the regulatory role of CpsY provides a unique system for understanding the complex
adaptive responses of invasive pathogens to the various stresses imparted by the host. Streptococcal
pathogens appear to be able to coordinate nutritional stress responses by upregulation of virulence
factors to acquire nutrients from the host, while at the same time limiting their own destruction by
modifying their cell wall to protect against self autolysins and host antimicrobial defenses. While
many of the specific details within these complex and highly integrated stress response pathways
remain to be elucidated, their high degree of conservation among prokaryotes, and the severe loss of
pathogenicity

upon

their

disruption

would

indicate

these

as

good

therapeutic

targets.
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ABSTRACT
PLEIOTROPIC REGULATORY FUNCTION OF THE LysR FAMILY TRANSCRIPTIONAL
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The ability of a pathogen to metabolically adapt to the local environment for optimal
expression of virulence determinants is a continued area of research. Orthologs of the Streptococcus
iniae LysR family regulator CpsY have been shown to regulate methionine biosynthesis and uptake
pathways, but appear to influence expression of several virulence genes as well. A S. iniae mutant
with an in-frame deletion of cpsY (cpsY) is highly attenuated in a zebrafish infection model. The
cpsY mutant displays a methionine-independent growth defect in serum, which differs from the
methionine-dependent defect observed for orthologous mutants of S. mutans and S. agalactiae. On the
contrary, the cpsY mutant can grow in excess of WT when supplemented with proteose peptone,
suggesting an inability to properly regulate growth. CpsY is critical for protection of S. iniae from
clearance by neutrophils in whole blood, but is dispensable for intracellular survival in macrophages.
Susceptibility of the cpsY mutant to killing in whole blood is not due to a growth defect because
inhibition of neutrophil phagocytosis rescues the mutant to WT levels.

S. iniae does not alter

neutrophil phagosomal maturation, but instead is able to adapt to the extreme bactericidal environment
of a mature neutrophil phagosome dependent upon CpsY. This CpsY-dependent adaptation appears to
involve stabilization of the cell wall in part through peptidoglycan O-acetylation and repression of
cellular autolysins. In addition, CpsY may influence these processes by responding to nutritional
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stress. The ability of a pathogen to evade neutrophil phagocytic killing mechanisms is critically
important for dissemination and establishment of a systemic infection. Understanding how pathogens
overcome these innate defenses is important for the development of optimal therapeutic strategies for
invasive infections. Furthermore S. iniae proves to be a powerful model to investigate bacterial
adaptations during systemic streptococcal infection.
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